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DISSERTATION SYNOPSIS   
BACKGROUND:  
Major advances have been made in preventing mother to child transmission of HIV (PMTCT), 
as well as in decreasing morbidity and mortality amongst HIV-infected infants and children. 
However, maintenance of excellent adherence to combination antiretroviral therapy (cART) 
lifelong is required to achieve optimal benefits. In addition, treatment options for children 
are limited by potential drug-resistance following PMTCT exposure, availability of 
appropriate and palatable formulations, long-term toxicity concerns and drug-
interactions—notably with co-treatment for tuberculosis. Given these challenges, drug 
simplification strategies for children remains an important area of research.   
The World Health Organisation (WHO) recommends lopinavir/ritonavir-based (LPV/r) cART 
as first-line for children <36 months old with the option to substitute LPV/r with a 
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nonnucleoside reverse transcriptase inhibitor if virologic suppression is maintained. This 
simplification strategy is potentially cost-saving, regimen-sparing and more tolerable, with 
a better long-term side-effect profile. Consequently, benefits should also exist in terms of 
adherence. The main evidence in support of this strategy has come from trials conducted 
by the Nevirapine Resistance Studies (NEVEREST) group. In particular, the NEVEREST 3 trial 
showed that substituting LPV/r for efavirenz (EFV) in children aged 36-60 months 
virologically suppressed on LPV/r-based cART was protective against viral rebound and had 
no effect on virological failure compared with remaining on LPV/r. To our knowledge, no 
studies to date have examined the virologic outcomes of children changed to an EFV-based 
regimen after initiating a LPV/r based regimen in routine, resource-constrained settings 
where selection of patients as eligible for EFV substitution and subsequent monitoring 
practices may be less rigorous than in a trial setting.   
At the International Epidemiologic Database to Evaluate AIDS—Southern Africa 
collaboration’s (IeDEA-SA) South African sites LPV/r has been used for first-line cART in 
children <36 months of age irrespective of PMTCT antiretroviral exposure. At many of these 
sites clinicians have, at their discretion, elected to substitute LPV/r with EFV when children 
reach 36 months of age. This has provided the opportunity to conduct an observational 
study to investigate this practice in a routine-care setting – comparing outcomes in children 
virologically suppressed and ≥36 months old who underwent a substitution of LPV/r to EFV 
(substitution group) to those who remained on their initial LPV/r-based regimen (stay 
group).  
We hypothesized that HIV-infected, cART-naive children who have had no more exposure 
to NVP than a single postpartum dose, who achieve and maintain virologic suppression on 
initial LPV/r-based cART and subsequently undergo a single drug substitution from LPV/r to 
EFV, do no worse virologically than comparable children who remain on LPV/r-based cART.  
METHODS:  
Structured literature review  
The objectives of the literature review were to review the existing published research on 
cART regimen simplification strategies in children (with a particular focus on those 
substituting a PI with an NNRTI in children who had achieved virologic suppression on the 
PI) and to provide an understanding of how simplification strategies relate to adherence, 
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drug resistance and adverse events, and to contextualise this within a resource-limited 
setting.  
A Pubmed and Google Scholar search identified articles relating to PI to NNRTI substitutions 
in virally-suppressed children on cART in resource-constrained settings. Due to a dearth of 
literature examining such single drug-class substitutions, the search was expanded to other 
drug simplification strategies.  
Retrospective cohort study  
We conducted a retrospective review of cohort data prospectively collected between 2003 
-2010 by the IeDEA-SA collaboration. Only data from the 8 South African sites were included.  
The primary aim was to compare between children in the substitution and stay group the 
probability of virologic non-suppression within 2 years of substitution (or an equivalent time 
point in the stay group).  
The primary objectives were to describe the group of children who had EFV substituted for 
LPV/r and those who remained on LPV/r; to determine the probability undergoing a LPV/r 
to EFV substitution at approximately 36 months of age and identify characteristics 
associated with this cART change; and to compare the probability of virologic failure and 
time to virologic non-suppression in the stay and substitution groups after adjusting for 
predictors of poor virologic outcomes.   
All HIV-infected children initiated on LPV/r-based cART who achieved and maintained 
virologic suppression by 36 months of age and with follow-up beyond 36 months of age, 
were included. Characteristics of children who had LPV/r substituted with EFV between 36 
and 60 months of age were compared with those remaining on LPV/r using Wilcoxon rank 
sum, Chi-squared, and Fisher’s exact tests, as appropriate.   
The primary outcome was time to first HIV-RNA >400 copies/ml after 42 months of age (stay 
group) or after substitution (substitution group). Time to this endpoint was compared 
between the stay and substitution groups using Kaplan-Meier plots. The association 
between substitution of LPV/r with EFV and the primary outcome was assessed using Cox 
proportional hazard models adjusted for other predictors of virologic non-suppression. The 
initial description included the proportion of children lost-to-follow-up, transferred for care 
at another health facility, or who died after 42 months of age (stay group) or after date of 
substitution (substitution group).  
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RESULTS:   
Structured literature review   
The review identified very little published data on the topic. There was no routine care data 
apart from a few small case series. The available data did seem to support the idea of such 
a simplification strategy, although apart from the NEVEREST studies, all other studies only 
included children with no prior exposure to NNRTI for PMTCT or treatment.  
Retrospective cohort study  
Of 690 children included, 36 underwent substitution at a median age of 44.1 months. 
Groups were similar at baseline (age, anthropometry, clinical and immunological stage, HIV-
RNA, cART regimen) and at 42 months/date of substitution. Thereafter, the probability of 
having an HIV-RNA >400 copies/ml was not significantly different between the substitution 
and stay groups, adjusted for other predictors of virologic rebound  (adjusted HR 1.43, 95% 
CI 0.62; 3.30, p=0.396).  
  
CONCLUSION:  
In this observational study, children virally suppressed on LPV/r-based cART changed to 
EFV did no worse virologically than those remaining on LPV/r. This may be an effective 
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1. SUMMARY  
1.1. Background   
The 2013 World Health Organisation (WHO) guidelines for antiretroviral treatment of 
children recommend a lopinavir/ritonavir (LPV/r) based combination antiretroviral 
therapy (cART) regimen for all children <36 months old, with the option to substitute LPV/r 
with a non-nucleoside reverse transcriptase inhibitor (NNRTI) in children with sustained 
viral suppression. Few studies describe the outcomes of this practice in routine, resource-
limited settings and those that have mostly excluded children with post-partum NNRTI 
exposure.  
Among children who initiated a LPV/r-based regimen at <36 months of age, we aim to 
compare those who subsequently underwent a substitution of LPV/r to EFV (substitution 
group) and those who remained on their initial LPV/r-based regimen (stay group) in terms 
of the probability of virologic non-suppression within 2 years after substitution (or an 
equivalent time point in the stay group).  
1.2. Methods  
We will do a retrospective cohort study. All HIV-infected children at International 
Epidemiologic Database to Evaluate AIDS - Southern Africa (IeDEA-SA) sites initiated on 
LPV/r-based cART at <36 months of age from 2003 to 2010, who achieve and maintain 
virologic suppression by 36 months of age and with follow-up beyond 36 months of age, 
will be included.   
Characteristics of children who had LPV/r substituted with EFV between 36 and 60 months 
of age will be compared with those remaining on LPV/r using Wilcoxon rank sum, Chi-
squared, and Fisher’s exact tests, as appropriate.   
The primary outcome will be time to first HIV-RNA >400 copies/ml after 42 months of age 
(stay group) or after substitution (substitution group). Time to this endpoint will be 
compared between the stay and substitution groups using Kaplan-Meier plots. The 
association between substitution of LPV/r with EFV and the primary outcome will be 
assessed using Cox proportional hazard models adjusted for other predictors of virologic 
non-suppression.  
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1.3. Anticipated outcome and benefits  
We anticipate that the group of children who experience a single-class drug substitution 
from LPV/r to EFV will do no worse virologically than those who remain on LPV/r-based 
cART. However, we anticipate this may not be true for children exposed to more than a 
single post-partum dose of nevirapine administered for prevention of mother to child 
transmission of HIV.  
Potential benefits include knowledge gained about whether children can safely have their 
antiretroviral treatment regimen simplified without increased risk of virologic 
nonsuppression or virologic failure.  
2. ABBREVIATIONS AND DEFINITIONS 2.1. 
Abbreviations  
3TC   lamivudine  
ABC  abacavir  
ARV  antiretroviral  
AZT   zidovudine  
cART  combination antiretroviral treatment  
CHER  Children with HIV Early Antiretroviral Therapy study  
D4T  stavudine  
EFV   efavirenz  
HIV   human immunodeficiency virus  
HIV-RNA  HIV ribonucleic acid quantitative PCR measurement of viral load  
IeDEA-SA  International Epidemiologic Database to Evaluate AIDS - Southern Africa  
LPV/r  lopinavir/ritonavir  
NEVEREST   Nevirapine Resistance Study  
NNRTI  non-nucleoside reverse transcriptase inhibitor  
NRTI  nucleoside reverse transcriptase inhibitor  
NVP  nevirapine  
PCR  polymerase chain reaction  
PI   protease inhibitor  
PMTCT  prevention of mother to child transmission of HIV  
WHO  World Health Organisation  
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2.2. Definitions  
Loss-to-follow-up  
No recorded visit in the 9 months prior to database closure  
Stay group   
Children started on LPV/r-based cART before 36 months of age whose HIV-RNA is <400 
copies/ml on cART at 36 months of age and who do not undergo a drug-class change by  
60 months of age   
 Substitution group    
Children started on LPV/r-based cART before 36 months of age whose HIV-RNA is <400 
copies/ml on cART at 36 months of age and who are subsequently changed to EFV-based 
cART as a single drug substitution where the substitution was not documented as being 
due to failure, toxicity or contra-indication and takes place between 36-60 months of age  
Time to virologic non-suppression  
Time from 42 months of age (stay group) or date of substitution (substitution group) until 
first HIV-RNA measure of >400 copies/ml  
Values at cART initiation  
The value of a specific parameter measured closest to the date of ART initiation will be 
considered to be the baseline value at ART initiation provided it was taken within a 
particular window around the date of ART initiation. The windows are within 180 days pre 
and 7 days post starting cART (CD4 count/percent and HIV-RNA)  or within 35 days pre 
and 14 days post starting ART (weight and height)  
Viral blip  
An isolated viral load >1000 copies/mL which subsequently returns to <400 copies/mL 
within 24 months with no change in cART regimen  
Virologic failure  
Two consecutive HIV-RNA measures of >1000 copies/mL whilst on cART where the two 
measures are taken within one year, at least 1 month apart and at least 6 months after 
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3. INTRODUCTION  
3.1. Problem Identification  
Sub-Saharan Africa carries 71% of the global burden of HIV, including 88% of new 
childhood infections (Joint United Nations Programme on HIV/AIDS Nations [UNAIDS], 
2012). Prevention of mother-to-child transmission of HIV (PMTCT) strategies are 
improving, with fewer children becoming vertically-infected with HIV (United Nations 
Children’s Fund [UNICEF] 2013:6). Moreover, health outcomes of vertically-infected 
children have vastly improved with the use of combination antiretroviral treatment 
(cART), most notably if started early in infancy, as demonstrated in the CHER study (Violari 
et al, 2008:2241).   
However, these outcomes are dependent on excellent levels of adherence to 
antiretrovirals, lifelong. Given the lifelong nature of the treatment, virologic failure is at 
some point almost inevitable, and the development of long-term side-effects is of concern 
(Arpadi et al, 2013). Ideally long-term regimens need to be effective, have a good safety 
profile and be simple so as to promote adherence. Furthermore, recommended paediatric 
regimens need to take into account the possibility of primary or secondary resistance to 
drugs used for PMTCT in infants who become infected despite such preventative 
measures. The greatest concern is around the non-nucleoside reverse transcriptase 
inhibitor (NNRTI) class; particularly nevirapine (NVP) and efavirenz (EFV).   
Nevirapine has firmly established itself as the drug of choice for infants in PMTCT 
programmes, with good effect. Initially used as a single post-partum dose to the infant, 
NVP monotherapy is increasingly becoming used for ≥4 weeks as infant prophylaxis, 
especially in areas where exclusive breastfeeding is encouraged for infant health. In 
addition, as EFV-based cART becomes more widely used for pregnant and breastfeeding 
women both for their own health and as PMTCT, HIV-exposed infants are exposed to EFV 
for long durations (WHO, 2013:100-107).   
Both NVP and EFV have a low genetic barrier to resistance and cross-resistance occurs 
between NVP and EFV. Thus, infants who fail PMTCT interventions are at risk of acquiring 
NNRTI-resistant HIV or developing it de novo (Fogel et al, 2013). Moreover, these 
resistance mutations have been shown to persist, which raises concern about the efficacy 
of NVP or EFV in cART regimens of children who have failed PMTCT (Hunt et al, 2011).  
Nevirapine is no longer recommended by the World Health Organisation (WHO) for 
firstline use in children <36 months of age (WHO, 2010); the protease-inhibitor (PI) 
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lopinavir/ritonavir (LPV/r) is recommended instead, irrespective of infant exposure to NVP 
during PMTCT. This is because LPV/r has shown better viral suppression, durability and 
robustness in children compared with NVP (Palumbo et al, 2010; Violari et al, 2012).   
However, LPV/r formulations are expensive, have food and refrigeration requirements, 
require twice-daily dosing, are poorly palatable and have long-term metabolic sideeffects. 
Use of a protease inhibitor (PI) in the first-line may also make second-line drug choices 
difficult.  
Consequently, the 2013  WHO “Consolidated Guidelines on the Use of Anti-Retroviral 
Drugs for Treating and Preventing HIV Infection” (WHO, 2013) recommend an initial LPV/r-
based cART regimen for all children <36 months of age, with the option to substitute LPV/r 
with an NNRTI in children with sustained viral suppression (WHO,  2013:122).   
This conditional recommendation attempts to provide children with a simplified longterm 
regimen that avoids the challenges associated with prolonged LPV/r use. This is a 
simplification strategy which is potentially cost-saving, regimen-sparing and more 
tolerable, with a better long-term side-effect profile (Vigano et al.2005). Consequently, 
benefits should also exist in terms of adherence. The main evidence in support of this 
strategy has come from the Nevirapine Resistance Studies (NEVEREST).   
In 2010, the NEVEREST group published results of a  randomised controlled trial in which 
NVP was reused as treatment in children <2 years old who had been exposed to it as a 
single dose during PMTCT once they had achieved virologic suppression on a LPV/rbased 
regimen (Coovadia et al, 2010). This showed favourable virologic outcomes for the NVP 
substitution arm in the short term; although by one year post-substitution a significantly 
greater proportion of children in the substitution arm had failed virologically. Routine viral 
load monitoring post-substitution was recommended as a safety mechanism to identify 
failures. This was also borne out in the long-term follow-up of the trial participants (Kuhn 
et al, 2012).    
Pre-treatment genotypic resistance patterns for the trial participants were subsequently 
analysed in a cross-sectional study (Hunt et al, 2011). NNRTI mutations were present in 
27% of pre-treatment blood samples overall, with prevalence decreasing with increasing 
age such that by 18 months of age all samples showed wild-type virus. In the LPV/r-toEFV 
substitution group a significant association was found between pre-treatment NNRTI 
resistance mutations and virologic failure within 52 weeks of the drug substitution. 
However, where NNRTI-resistant mutations were present in <25% of the viral population, 
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they did not negatively affect the child’s response to NVP once initially supressed on LPV-
r-based ART (Hunt et al, 2011:1468).   
These findings suggest that initial suppressive LPV/r-based cART in children exposed to 
perinatal NVP may “raise the threshold of the frequency of resistance mutations required 
to result in clinically significant differences in virologic response to therapy” (Hunt et al, 
2011:1467).These findings were supported by Moorthy et al (2011), who concluded that 
standard HIV resistance genotyping methods should be able to identify children who could 
benefit from a LPV/r-to-NVP substitution.    
In a second non-inferiority study (NEVEREST III) children who initiated LPV/r based 
regimens at <24 months old and had achieved an HIV-RNA <50copies/ml were 
randomised, at a median age of 4.1 years, either to continue LPV/r or have LPV/r 
substituted with EFV. These children had been exposed to perinatal NVP as prophylaxis. 
The trial was powered to look for a ≥10% difference in efficacy between the LPV/r and EFV 
arms. Both end-points of the trial — virologic non-suppression and virologic failure  
— showed EFV to be non-inferior to LPV/r in this subset of children (Coovadia et al, 2014 
– unpublished).  
Despite the promising preliminary results of the NEVEREST III study, there remains a 
concern about NNRTI resistance following the PMTCT use of NVP, particularly as very few 
children included in the study were exposed to more than a single dose of NVP as 
prolonged prophylactic use during breastfeeding was not recommended at the time that 
these children were infants.    
3.2. Justification  
To our knowledge, no studies to date have examined the virologic outcomes of children 
changed to an EFV-based regimen after initiating a LPV/r based regimen in routine, 
resource-constrained settings where selection of patients as eligible for EFV substitution 
and subsequent monitoring practices may be less rigorous than in a trial setting.   
The IeDEA-SA collaboration includes 8 South African ART sites where LPV/r has been used 
for first-line cART in children <36 months of age irrespective of PMTCT antiretroviral 
exposure. At many of these sites clinicians have, at their discretion, elected to substitute 
LPV/r with EFV when children reach 36 months of age. This provides the opportunity to 
conduct an observational study to investigate this practice in a routinecare setting – 
comparing virologic outcomes in children who underwent a substitution of LPV/r to EFV 
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(substitution group) to those who remained on their initial LPV/r-based regimen (stay 
group).   
4. STUDY HYPOTHESIS, AIM AND OBJECTIVES  
4.1. Hypothesis  
The study hypothesis is that HIV-infected, cART-naive children who have had no more exposure 
to NVP than a single postpartum dose, who achieve and maintain virologic suppression on 
initial LPV/r-based cART and subsequently undergo a single drug substitution from LPV/r to 
EFV, do no worse virologically than comparable children who remain on LPV/rbased cART.  
4.2. Aims and objectives  
4.2.1. Aim  
To compare virologic outcomes between children in the substitution and stay 
groups  
4.2.2. Primary objectives  
I. Describe and compare the children in the substitution and stay groups in terms 
of their immunological and anthropometric parameters at baseline and on 
cART (at 36 months of age and at either age at switch or 42 months of age, 
substitution and stay groups, respectively)   
II. Determine the probability undergoing a LPV/r to EFV substitution at 
approximately 36 months old and identify patient characteristics associated 
with this cART change  
III. Describe and compare between the stay and substitution groups the 
proportion of children lost-to-follow-up, transferred for care at another health 
facility, or who died after 42 months of age (stay group) or time of substitution 
(substitution group)  
IV. To compare the probability of virologic non-suppression between the 
substitution and stay groups within the 2 years after substitution (or an 
equivalent time point in the stay group), after adjusting for other predictors of 
virologic non-suppression.  
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5. METHODOLOGY  
5.1. Study design  
This will be an observational analytical study; a retrospective review of routine care data 
prospectively collected between 2003 -2011 by the IeDEA-SA collaboration.   
5.2. Characteristics of the study population and participating sites  
Only data from eligible South African sites (2 in Kwa-Zulu Natal, 4 in the Western Cape and 
2 in Gauteng) will be included. Of these sites, 7/8 are in urban settings and 7/8 are public 
sector clinics. Most sites provide primary level care with some providing secondary or 
tertiary level care. The sites serve mostly low income communities with high HIV 
prevalence, high levels of unemployment and inadequate housing and sanitation. The 
sites have previously been described in a paper by Davies et al (2009: 732).   
Participants will be HIV-infected children in care at the above sites (cohorts) who meet the 
eligibility criteria for children as described below.  
5.3. Eligibility criteria  
5.3.1. Eligibility criteria for IeDEA-SA cohorts:  
I. The site initiates children <36 months old on LPV/r-based cART regardless 
of PMTCT exposure  
II. The site has changed at least one child between 36-60 months of age from 
LPV/r to EFV as a single drug substitution where the substitution was not 
documented as being due to failure, toxicity or contra-indication  
5.3.2. Eligibility criteria  for children  
Inclusion criteria  
I. Children initiating  LPV/r-based cART with a backbone of 2 NRTIs at <36 
months of age  and remaining in care on a LPV/r based regimen until at least 
36 months of age  
II. Total follow-up must extend beyond 42 months of age   
III. Participants must have had a viral load measured in the 12 months prior to 
substitution (substitution group) or within the 12 months prior to turning 36 
months old (stay group)   
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Exclusion criteria  
I. No HIV-RNA viral load monitoring data after 36 months of age  
II. Children who never achieved a viral load measure of <400copies/mL on the 
initial LPV/r-based ART regimen  
III. Children who experienced virologic failure and  were switched to second-line 
cART prior to 36 months of age or who had defaulted by that age  
IV. Children enrolled on the NEVEREST trial (which was conducted at one of the  
IeDEA-SA sites)  
5.4. Outcomes  
5.4.1. Primary outcomes  
 I.  Time to viral non-suppression   
Time from 42 months of age or date of substitution to first HIV RNA >400 
copies/ml   
 II.  Viral failure   
Two consecutive HIV-RNA measures of >1000copies/ml whilst on cART, taken 
within one year and at least 1 month apart, the first measure being at least 6 
months after date of single drug substitution or 42 months of age  
5.4.2. Secondary outcomes  
I. Probability of transfer out to another health facility for ongoing cART  
management, loss-to-follow-up or death  
5.5. Data collection methods  
Data was collected by participating sites in a standardised manner according to the IeDEA-
SA Standard Procedure for Data Transfer, Version 2.0  / 2010 (Appendix 1) and transferred 
to the IeDEA Data Centre at the University of Cape Town.   
Unique, anonymous patient identifiers were used, with each local site collaborator being 
responsible for maintaining the key linking the patient identifier with the patient.  
The South African National Department of Health Guidelines 2004 (National Department 
of Health [NDOH], 2004) and 2010 editions (NDOH, 2010) - were used by all sites to 
determine when children met qualifying criteria for cART, to initiate first-line cART 
regimens in a standard manner, and to monitor the efficacy and safety of cART using 
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routine clinical review and laboratory tests. Prior to 2004 local treatment protocols based 
on Centres for Disease Control (CDC) antiretroviral treatment guidelines were followed.  
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Until 2010, children <36 months old were initiated on cART if they had a WHO clinical 
stage 3 or 4 condition, or fulfilled the national guideline age-specific criteria for severe 
immune suppression. From 2010 onwards children <12 months of age were eligible for 
cART immediately irrespective of disease severity or CD4 count.    
In terms of efficacy monitoring, South African NDOH guidelines recommended that 
routine HIV-RNA measurement be performed bi-annually, or 3 months after a value 
>1000copies/ml, with bi-annual (changing to annual in 2010) CD4 count and percentage 
monitoring.  
Recommended safety monitoring included a full blood count, alanine transferase, total 
cholesterol, triglycerides and glucose performed at initiation of cART and then biannually, 
depending on the specific antiretroviral drugs used (NDOH; 2004:47-8). The 2010 
guidelines recommended that, after the first 6 months of cART, routine annual full blood 
count, total cholesterol, triglycerides glucose measurement, and clinically-driven alanine 
transferase measurement be taken, depending on the specific antiretroviral drugs used 
(NDOH; 2010:31).   
In practice, however, safety and efficacy monitoring and the recording of results in routine 
databases is unlikely to be fully completed according to the schedule recommended in the 
guidelines.  
First-line cART regimens for children <36 months changed over time but were comprised 
of a backbone of 2 NRTIs (D4T or AZT or ABC plus 3TC) with either LPV/r or LPV/r plus 
ritonavir if on concomitant anti-tuberculosis (TB) treatment. Children on an NRTI 
backbone with ritonavir alone (i.e. those on TB treatment or those <6 months of age, 
according to the 2004 guidelines) were not included.  
Drug regimens and any regimen changes were recorded, as were the reasons for any drug 
changes made to the initial regimen.   
5.6. Sample size and power considerations  
We assume the probability of undergoing a LPV/r to EFV substitution to be 10%; the 
probability of VL detection in the stay group to be 20%; and the probability of administrative 
censoring in both groups to be 10%. With these assumptions, Table 1 gives the range of 
total sample sizes required to in order to detect a difference in probability of VL detection 
between the substitute and stay groups ranging from 10 – 20% with 80% power and alpha 
= 0.05.  
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We expect approximately 1000 patients to meet our eligibility criteria; hence we will have 
80% power to detect an increase in non-suppression of at least 12% (i.e. a probability of 
non-suppression of 32%).    
Total sample size 
required  
Probability of VL detection* 
in the stay group  
Probability of VL detection* 
in the substitution group   
Hazard 
Ratio  
338  0.20  0.40  2.29  
423  0.20  0.38  2.14  
543  0.20  0.36  2.00  
719  0.20  0.34  1.86  
992  0.20  0.32  1.72  
1448  0.20  0.30  1.60  
* VL detection limit >400 copies/ml 
Table 1.  Sample size considerations  
5.7. Data analysis and statistical methods  
Characteristics of children at cART initiation, at 36 months of age and at 42 months of age 
(stay group) or date of LPV/r to EFV change (substitution group) will be described. This will 
be done using frequency tables and proportions for categorical data; and mean plus 
standard deviation (SD) or median plus interquartile range (IQR) for normally and non-
normally distributed numerical data, respectively.  Characteristics of children at the above 
time points will be compared between the stay and substitution groups using Chisquared 
or Fisher exact tests for categorical data and t-tests or Wilcoxon sum rank for normally 
and non-normally distributed numerical data, respectively.  
Logistic regression methods will be used to examine associations between clinically 
relevant predictors of drug substitution and the probability of having undergone a LPV/r 
to EFV change.   
Time to viral non-suppression will be measured from age 42 months (in the stay group) or 
date of substitution (in the substitution group) as the median age of substitution is likely 
to be >36 months. This is because children only become eligible for substitution from 36 
months of age and will need some follow-up time during which the substitution could 
occur. Time from age 42months or date of substitution to viral non-suppression (Figure 
1.) will be estimated using Kaplan Meier plots. The effect of substitution and relevant 
patient characteristics at cART initiation and at age 42 months old/date of substitution on 
time to virologic non-suppression will initially be explored using KaplanMeier plots 
stratified by each of these variables.  
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Figure 1. Schematic for chosen time points of interest  
A Cox proportional hazards model, built in a manual stepwise fashion, will be used to 
examine the effect of changing from LPV/r to EFV after 36 months of age on the 
probability of subsequent viral non-suppression within 24 months, adjusted for other 
known predictors of virologic failure.   
Potential explanatory variables to be included a priori are: age, clinical stage, CD4 count, 
HIV-RNA measurement and weight-for-age z-score (WAZ) at cART initiation; perinatal NVP 
exposure; CD4 count and WAZ at date closest to 42 months of age or point of substitution; 
and HIV-RNA blips to >400 copies/mL whilst on cART but before 36 months of age.   
Variables with a p-value of <0.1 will be included in the Cox model. Models will be 
compared using Aikaike’s information criterion (AIC) or the log-likelihood ratio test for 
non-nested and nested models, respectively. The final model’s goodness of fit will be 
checked using Cox-Snell residuals. Schoenfeld residuals will be used to test whether the 
model meets the proportional hazards assumption. The form of the explanatory variables 
will be checked using Martingale residuals, whilst outlying and influential points will be 
identified using deviance residuals. The substitution variable will then be added to the 
final model, and interpreted.  
A p-value of <0.05 will be considered statistically significant.  
Data will be analysed using STATA®/IC 11.1 for Windows Data Analysis and Statistical 
Software (StataCorp LP, 4905 Lakeway Drive, College Station, TX 77845, USA).  
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6. ETHICAL CONSIDERATIONS  
The data to be used for this analysis are anonymised and will be obtained from individual 
IeDEA sites. The University of Cape Town (South Africa) and University of Bern 
(Switzerland) have Institutional Review Board (IRB) approval to curate the dataset and 
conduct analyses; the requirement for informed consent for contribution of data to the 
IeDEA-SA database has been waived as only anonymised data collected as part of routine 
monitoring is contributed. Each site has existing IRB approval for contribution of data to 
IeDEA collaborative analyses (Appendix 2).  
The study does not require participants to attend any additional visits, and does not require 
any additional blood tests or clinical monitoring to be performed; data collected is from 
the participants’ routine care visits.  
Given the retrospective, observational nature of the study it is not anticipated that the 
participants will incur any risks. The only potential risk is a breach of confidentiality. To 
protect against this risk all patient data is anonymised before transfer to the IeDEA 
database. The IeDEA-SA database is stored on a secure server at the University of Cape 
Town with user-level access controls restricted to only the named IeDEA-SA data 
managers. The analysis dataset will be securely stored on the student’s personal computer 
in password-protected files. Once the analysis is complete and any manuscripts produced 
have been accepted for publication, the analysis dataset and files will be returned to UCT 
for secure archiving on the IeDEA-SA server, and all patient data on the student’s computer 
will be permanently deleted.   
Participants will not derive any individual direct benefit. However, the findings of this 
observational study of a routine-care treatment simplification strategy in a resourcelimited 
setting may benefit children on cART more broadly.  
7. STUDY LOGISTICS  
7.1. Budget  
The National Institutes of Health provides funding for the IeDEA-SA collaboration’s staff 
and collection and storage of data (Grant number: U01AI069924) through the National 
Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human 
Development and the National Cancer Institute. No additional funding support is required 
and the student will not be funded to conduct the analysis.  
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7.2. Timeline    
Year  
Month  
2003 -2011   2013   2014   
    Sep  Oct  Nov  Dec  Jan to June  Jul  Aug  
Data collection  x  x                  
Data acquisition 
and cleaning  
    x  x              
Data analysis        x  x  x          
Write-up              x  x      
Dissemination to 
stakeholders  
                x    
Submission                    x  
                      
7.3. Stakeholders   
Investigators at the contributing paediatric clinical sites:  
- Red Cross War Memorial Children’s Hospital, Cape Town: Assoc Prof Brian Eley  
- Tygerberg Academic Hospital, Cape Town: Dr Helena Rabie  
- Harriet Shezi Children’s Clinic, Chris Hani Baragwanath Hospital, Soweto: Dr Harry 
Moultrie  
- Médecins Sans Frontières South Africa and Khayelitsha ART Programme, Khayelitsha: Dr 
Vivian Cox  
- Gugulethu Community Health Centre, Cape Town: Prof Robin Wood  
- Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, 
Johannesburg: Dr Karl Technau  
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, 
Maryland, USA: Prof Lynne Mofenson  
IeDEA-SA:  
- School of Public Health and Family Medicine, University of Cape Town, South Africa: Dr 
Mary-Ann Davies  
- Institute of Social and Prevention of Medicine, University of Bern, Switzerland: Prof 
Matthias Egger  
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7.4. Dissemination of study results  
The results will be circulated to all of the participating IeDEA-SA sites. An abstract will be 
submitted to an appropriate conference and the manuscript reporting the study will be 
made publicly available through submission to a peer-reviewed scientific journal.  
8. STUDY LIMITATIONS  
Given the stringent ex- and inclusion criteria, and the fact that single-drug substitution is 
not a routine practice, the number of children that can be included in the analyses may be 
small. This is of particular concern in the substitution group.  
Being a retrospective cohort study, other potential limitations could occur due to missing 
or incomplete data and loss to follow-up of participants. Particularly relevant would be 
missing information on the nature and duration of exposure to PMTCT antiretrovirals; 
exposure to maternal NVP or EFV via breastfeeding; missing HIV-RNA data at cART 
initiation; and missing data at the window around 36months of age as children may not 
have had a variable measured within the specified window. This may lead to a biased 
comparison between the stay and substitution group as we may not fully be able to adjust 
for confounding in the analysis. This applies both to missing data on measured as well as 
unmeasured confounders e.g. adherence. We will use viral blips prior to 36 months of age 
whilst on cART as a proxy for adherence.   
As the data comes from routine practice, children may have periods with scanty data (e.g. 
may fall out the system then re-enter). Furthermore, with children being lost-to-followup 
or transferred to a different treatment site, follow-up duration may be limited and there 
may be under-ascertainment of both mortality and virologic failure (or nonsuppression). 
In terms of mortality this is not a major concern for this study as most mortality occurs 
early after cART initiation, whereas the eligibility criteria for this study require children to 
have been in care and on cART for at least 6 months.  Clinicians may also be biased towards 
not transferring out children in whom they have elected to substitute LPV/r with EFV – 
either related to the reason for the substitution or to clinical anxiety about the decision. 
Also, children doing well on LPV/r could be more likely to be transferred out so the results 
in the stay group might be biased in favour of children more likely to have non-suppression.  
Clinicians may have been reluctant to substitute LPV/r with EFV in children known to have 
had previous exposure to NVP for PMTCT; thus we may not be able to examine the effect 
of the substitution strategy in children with prior PMTCT exposure. In addition, during the 
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period this data was collected the minimum standard of care for PMTCT was a single-dose 
of NVP to the mother in labour and to the infant immediately post-partum. Some provinces 
may have added AZT for 7 or 21 days to the infant regimen. Extended infant NVP 
prophylaxis (i.e. 6 weeks in all HIV exposed children and throughout the duration of 
breastfeeding; or either 4 or 12 weeks post-partum regardless of infant feeding choice, 
depending on risk) was not the standard of care; neither was (EFV-based) cART for all 
pregnant/breastfeeding women. Extended exposure to NNRTIs both ante- and postnatally 
is now the standard of care. Thus the findings of this study may not be generalizable to 
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1. INTRODUCTION  
Sub-Saharan Africa carries 71% of the global burden of HIV (Joint United Nations 
Programme on HIV/AIDS Nations [UNAIDS] 2012). An estimated 810 new childhood 
infections occur every day (United Nations Children’s Fund [UNICEF] 2011). Fortunately, 
prevention of mother-to-child transmission of HIV (PMTCT) strategies are improving with 
vertical transmission rates, even in resource-limited settings, now as low as 2-5% 
(Grimwood et al, 2012).   
Nevirapine (NVP) is firmly established as the drug of choice for infant prophylaxis in PMTCT 
programmes. Initially used as a single post-partum dose to the infant, NVP monotherapy is 
increasingly used for ≥4 weeks as infant prophylaxis, especially where exclusive 
breastfeeding is encouraged for infant health and mothers are not on combination 
antiretroviral therapy (cART). Where long-term maternal cART is instituted; i.e. World 
Health Organisation (WHO) Option B or B+ (WHO, 2013); breastfeeding infants face 
potential exposure to non-nucleoside reverse-transcriptase inhibitors (NNRTI) for 
extended periods via breast milk.   
Early HIV testing and initiation of cART has vastly improved health outcomes in 
verticallyinfected children (Violari et al, 2008). These outcomes require excellent levels of 
adherence to antiretrovirals, lifelong. Given the lifelong nature of the treatment, virologic 
failure is at some point almost inevitable. Children are especially vulnerable as their 
duration of treatment is necessarily longer. Additionally, they may have either developed 
NNRTI resistance due to the use of infant NVP or may have inherited NNRTI resistant HIV 
given the use of maternal NVP or EFV for PMTCT, thereby limiting their treatment options 
(Hunt et al, 2011; Micek et al, 2014; Zeh et al, 2011; Lockman et al, 2007).  
The WHO 2013 guidelines recommend lopinavir/ritonavir-(LPV/r) based cART for children  
<36 months of age, irrespective of NVP exposure (WHO, 2013:122). This is due to better 
viral suppression and durability of LPV/r compared with NVP (Palumbo et al. 2010; Violari 
et al. 2012) as well its higher genetic barrier to resistance (Tang & Shafer, 2012:e4). But 
LPV/r formulations are expensive, have food and refrigeration requirements, require 
twice-daily dosing, are poorly palatable and have unfavourable long-term metabolic 
sideeffects (Arpadi et al, 2013). Their use in the first-line makes second-line drug choices 
difficult.  In low-income settings, treatment cost (drug, personnel and laboratory costs) and 
transport, storage and food requirements are also important considerations.  
Drug simplification strategies, particularly those using safer drugs of comparative efficacy 
to those recommended in first line regimens for children, are important. Since the early 
2000’s researchers have attempted various cART simplification strategies, including:   
• decreasing dosing intervals to once-daily   
• using fixed-dose combinations (difficult given dose adjustment needed for growing 
children)  
• using drugs that are more palatable, easier to administer or have fewer unfavourable 
side-effects   
• planned treatment interruptions  
In 2013 WHO added a conditional recommendation to substitute LPV/r with an NNRTI in 
children with sustained virologic suppression based on concerns of toxicity from longterm 
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PI use; cost, transport and availability of LPV/r syrup in areas with inadequate 
infrastructure; vs. the risk of NNRTI resistance following PMTCT use of NVP (WHO 
2013:122). This simplification strategy is potentially cost-saving, regimen-sparing, simpler 
and more tolerable, with a better long-term side-effect profile (Penazzato et al, 2014; 
Vigano et al, 2005). Consequently benefits should exist in terms of adherence. However, 
there is fairly limited evidence for this recommendation. Additionally, few studies to date 
describe the virologic outcomes of this practice in routine, resource-constrained settings.  
  
2. OBJECTIVES OF THE LITERATURE REVIEW  
  
2.1. Primary objective  
Review the existing published research on antiretroviral regimen simplification 
strategies in children, with a particular focus on those substituting a PI with an NNRTI 
in children who had achieved virologic suppression on the PI.  
  
2.2. Secondary objective  
Provide an understanding of how simplification strategies relate to adherence, drug 
resistance and adverse events; to contextualise this within a resource-limited setting, 
and to explore other simplification strategies.  
    
  
3. SEARCH STRATEGY  
An electronic literature search was performed using Pubmed® (accessed via University of 
Cape Town (UCT) Libraries website) and Google Scholar (via Read Cube©).  A “population, 
intervention, comparison, outcome” (PICO) strategy was used, with exclusion terms (E), 
limits/restrictions (L) and secondary outcomes (2°) defined as outlined (Table 1).  
All study designs were included. The search was limited to human subjects, English 
language text and published articles. Within these limitations the search was exhaustive as 
pertaining to LPV/r to EFV single-drug substitution for simplification in children on cART, 
but was directed with regard to the secondary objectives. Given the paucity of published 
literature on LPV/r to EFV single drug substitutions in children, the search was broadened 
(Table 1).  
Article abstracts were scanned. Full-text versions articles meeting the primary and 
secondary objectives were downloaded via UCT Libraries (http://www.lib.uct.ac.za/). 
Additional articles were included by cross-referencing the articles included.  
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4. REVIEW AND INTERPRETATION OF THE LITERATURE  
  
Of 32 articles identified, 5 met the primary objective. These are summarised in Table 2. A 
6th study, the unpublished results of NEVEREST 3 which was presented at the Conference 
on Retroviruses and Opportunistic Infections (CROI) in Boston in 2014, is also included.   
  
Three of six studies were randomised controlled trials (RCT), which rank most highly in 
terms of quality and validity of evidence, but are limited in not reflecting routine care and 
may therefore not be generalisable. One was a single-arm open label trial and one was a 
small case series. Case series are vulnerable to multiple biases and provide poor quality 
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4.1. Unboosted-PI to EFV substitution with no prior NNRTI exposure:  
In 2003, in America, McComsey et al. published a prospective multi-centre singlearm 
open label trial which aimed to determine whether switching from PI- to EFVbased 
cART would improve metabolic parameters and maintain virologic suppression 
(McComsey et al, 2003:e275-81). Seventeen vertically-infected children with an HIV-
RNA viral load (VL) sustained at <400 copies/ml were included and followed-up for 48 
weeks. All completed the study. The median age was 10 years and the median 
duration of PI-based cART was 21 months. All were heavily pretreated but none had 
been exposed to NNRTIs. Bar one child, the PIs used were not ritonavir-boosted as 
this was not yet established practice and LPV/r was not yet licensed for use. All 
children were switched to EFV. Minor, transient neuropsychiatric side-effects were 
experienced, with reported improvement in quality of life and adherence. No clinical 
deterioration occurred and the CD4% improved marginally (35% to 38%) by week 48. 
This was statistically significant (p=0.03) although of doubtful clinical significance. 
Anthropometric measures remained stable. At week 48, 16/17 children had a VL <50 
copies/ml with one child having 61 copies/ml. Fasting triglycerides, total and low-
density lipoprotein (LDL) cholesterol were all significantly reduced by week 48 in those 
with high baseline values, and remained within normal limits in those with normal 
baseline values. No change in high-density lipoprotein (HDL) cholesterol was 
observed, although the cholesterol to HDL ratio improved favourably. No dietary 
changes were made during the study period.  
  
Study limitations included small size; possible selection bias; lack of a comparison 
group and blinding with potential observer or reporting bias; recall bias around 
adherence; measurement bias around anthropometric and laboratory measures (no 
detail is provided about standardisation of laboratory tests) and inter-observer bias 
for clinical response. Nonetheless, this study showed the PI-to-EFV switch to be 
virologically safe, have minimal side-effects and demonstrated an improvement in the 
metabolic profile in this group of heavily pre-treated children with no prior NNRTI 
exposure. It led to the hypothesis that nucleoside reverse transcriptase inhibitors 
(NRTI), not PIs, were potentially responsible for morphological changes in body fat 
distribution.  
  
In 2005 an Italian study looked at changing from PI- to EFV-based cART and amending 
the NRTI backbone by substituting stavudine (D4T) –emerging as the most likely drug 
causing lipoatrophy - with tenofovir (TDF) to “assess the impact on immunological, 
virological and metabolic parameters” in vertically-infected children (Vigano et al, 
2005:917). This prospective open-label RCT followed participants for 96 weeks. 
Results to 48 weeks were presented in the paper. Eligible children had to have 
maintained virologic suppression (VL <50 copies/ml) on a D4T, lamivudine (3TC) + PI 
regimen. As in the McComsey study, no child used lopinavir (LPV) and no child had 
used a ritonavir-boosted PI. Exclusion criteria included previous TDF or NNRTI use and 
a recent AIDS-defining illness. Of 28 children included, one was lost-tofollow up early 
in the study; 27 completed to week 48. The mean age was 12.1 (±3.9) years. 
Participants were randomised to change D4T to TDF and PI to EFV at baseline (Group 
1, n=14) or at week 24 (Group 2, n=13). At baseline the groups were comparable in 
terms of age, anthropometry, CD4 count and previous ARV exposure. Both groups 
were reviewed clinically and had monitoring (VL and CD4) and safety (fasting lipids) 
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bloods done at baseline and every 12 weeks until week 48. Urine analysis and serum 
creatinine, phosphate and bicarbonate measurement was conducted at baseline and 
at weeks 24 and 48.  All laboratory tests were validated and standardised.  
  
Vigano et al.’s findings supported McComsey’s. Three children experienced minor, 
transient neuropsychiatric side-effects after switching to EFV. Post-switch, adherence 
improved by participant self-report from 80% missing a dose in the preceding 2 weeks 
on the PI-regimen to 17% six months after switching. CD4 counts remained stable and 
children remained virologically suppressed to week 48.  Children in group 1 had a 
steady decrease in LDL cholesterol from week 12 - statistically significant at weeks 24 
and 48 (p<0.05 and <0.01, respectively). In contrast group 2 showed no change in LDL 
level prior to the switch from PI to EFV at week 24. However, after children in group 2 
switched, they too showed steady improvement in lipid profile (statistically significant 
at week 48, p<0.01). No renal impairment occurred in either group. Limitations 
included small sample size and a relatively short follow-up time. No mention was 
made of blinding of the statistician/data managers. A strength of the study was its 
design: RCT.  
   
4.2. Unboosted-PI to NVP substitution with no prior NNRTI exposure:  
In 2008 a Spanish group published a case series in which 7 HIV-infected, NNRTI-naive 
children with sustained virologic suppression on PI-based cART had the PI switched 
for NVP at the discretion of the treating clinician (Gonzalez-Tome et al, 2008). Reasons 
for the drug switch included regimen simplification (3/7), hyperlipidaemia (3/7) and 
lipodystrophy (1/7). The main objective was to describe the change in metabolic 
abnormalities following substitution but viral outcomes were also assessed. The 
median age of the children was 10 years and all were heavily pretreated with ARVs. 
Six children maintained a VL <50 copies/ml at 12 months. NVP was subjectively well 
tolerated.  
  
Limitations included study design (a small case-series thus no control group), 
information and measurement bias (e.g. no adherence questionnaire used, advice 
given about diet and exercise may have affected lipid profiles but was not measured 
or controlled for) and selection bias. It is unclear when the study took place and how 
many clinicians were involved. Nonetheless, the research findings supported those of 
the above two studies, albeit with NVP rather than EFV.  
  
4.3. Boosted-PI (LPV/r) to NVP substitution with prior NNRTI exposure:  
In 2010, Coovadia et al. published an open-label RCT substituting the PI in children’s 
first-line regimen for NVP in HIV-infected children who had been exposed to NVP as 
part of PMTCT; the NEVEREST1 trial (Coovadia et al, 2010:1082-1090). This was the 
first such trial in sub-Saharan Africa; the first specifically including children with prior 
NVP exposure; and the largest study addressing the question of virologic safety of 




1 The Nevirapine Resistance Study  
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Recruitment took place in Johannesburg, South Africa, from April 2005 to July 2007. 
The median age at randomisation was 20 months. All children had been exposed to 
NVP2 as part of PMTCT; all initiated PI-based cART according to South African national 
guidelines 3  (National Department of Health [NDOH], 2004); all had achieved and 
maintained virologic suppression (VL <400 copies/ml) within 12 months of starting 
cART.   
  
Children were randomised to either continue with LPV/r (or RTV3) or switch to NVP 
whilst keeping the NRTI backbone unchanged. The groups did not differ significantly 
either before cART initiation or at randomisation in terms of median age, VL, CD4%, 
WHO clinical stage or anthropometric measures. Children in both groups had been on 
LPV/r for a median of 9 months prior to randomisation. Both groups received 
adherence support; VL and CD4 cell counts were quantified at weeks 4, 16, 24, 36 and 
52 pre-randomization and at weeks 16, 24, 36 and 52 post-randomisation, 
respectively; neutrophil count and alanine transaminase (ALT) were measured at 
week 2 as well as at the time points above. Anthropometric data were collected 
throughout the study. Adherence was measured by weighing medicine returns (all 
syrup formulations). The primary end-point was any VL >50 copies/ml 
postrandomisation. Secondary end-points pertained to safety; one of which was 
having ≥2 VL >1000 copies/ml. Once adherence issues had been addressed, children 
in the switch group who met this safety end-point were put back onto LPV/r; those in 
the control group were changed to a second-line regimen.   
  
Children in the switch group were significantly less likely than those in the control 
group to meet the primary endpoint of any VL >50 copies/ml by 52-weeks 
postrandomisation (probability 0.438 vs. 0.576, respectively, p=0.02). However, the 
switch group (n=18/96) was more likely than the control group (n=2/99) to experience 
the secondary endpoint of virologic failure described above (probability 0.201 vs. 
0.022, respectively, p<0.001). Of the 18 children (20%) in the switch group who 
experienced ≥2 VL >1000 copies/ml, 3 re-suppressed on continuation of the switched 
regimen, 9 re-suppressed after being recommenced on LPV/r and 6 discontinued the 
study. Genotypic resistance testing was performed on 15/18 children; 13 had major 
NNRTI mutations – 10 of which were Y181C. Neither child in the control group had 
any major NNRTI mutations. Pre-randomisation HIV-resistance genotyping showed a 
strong relationship between existing major NNRTI mutations and achieving the 
secondary viral safety end-point (probability 0.447 in those with pre-existing 
mutations vs. 0.120 in those without, p=0.005). Children <12 months of age at cART 
initiation were more likely to have pre-randomisation genotypic resistance, but this 
did not translate to younger children having worse virologic outcomes. No major 
abnormality in ALT or neutrophil count occurred. CD4 counts improved in both groups 
over the study period, but the increases were likely clinically insignificant.  
  
 
2 The 2001 South African PMTCT guidelines allowed for a single dose of NVP to the mother in labour, 
and a single post-partum dose of NVP to the infant. Only in 2008 were these guidelines updated, 
advising ante- and intrapartum AZT to the mother and a 7 or 28 day course of infant AZT in addition to 
the single doses of NVP. 3 
 Children > 6mo: D4T, 3TC, LPV/r; children < 6mo or on concurrent anti-tuberculosis treatment: D4T,  
3 TC, RTV  
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The NEVEREST study had many strengths: it was well-designed; adequately powered; 
randomisation was good; laboratory tests were specified by make and were 
undertaken in a single laboratory; a modified intention-to-treat analysis was 
performed and the statistical methods were appropriate. Additionally, both switch 
and control groups had minimal loss-to-follow up (5.2 and 3.0%, respectively) and only 
4 children died during the study period—2 in each arm.  
  
The trial did have some weaknesses. Although it was conducted in a low-resource 
setting, frequent VL testing was done and was, in fact, recommended for safety should 
one choose to switch LPV/r to NVP. This is not necessarily possible in many resource-
constrained settings. Likewise, genotyping is difficult given the high cost. Secondly, 
the children recruited were born prior to 2010, and would thus have had only a single 
dose of NVP (sdNVP) as infant prophylaxis. In 2010 South Africa amended its PMTCT 
guidelines, replacing sdNVP with at least 6 weeks of NVP monotherapy for infant 
prophylaxis (NDOH. 2010:11-13). Lastly, length of follow-up may have been 
insufficient to identify all potential virologic failures.  
  
The NEVEREST group subsequently published an article in 2012 (Kuhn et al, 2005:521-
30) which presented results of 156 weeks of follow-up of the initial trial participants. 
These data showed the risk of viraemia >1000 copies/ml 156 weeks post-
randomisation no longer to differ significantly between substitution and control 
groups (0.330 vs. 0.281, respectively). Moreover, all those in the switch group who 
met the criteria for failure did so within the first 52 weeks post-randomisation. In the 
long-term, the switch group was significantly more likely to develop a mild to 
moderate transaminitis, but overall NVP was well tolerated. Overall the researchers 
concluded that NVP-exposed children who failed PMTCT but are virologically 
suppressed on LPV/r-based cART can safely undergo “pre-emptive switching to a 
nevirapine-based regimen” (Kuhn et al, 2012:529) and that this “might be a valuable 
treatment strategy to preserve ritonavir-boosted lopinavir for future treatment while 
minimising adherence challenges for parents, limiting metabolic toxic effects, and 
reducing cost” (Kuhn et al, 2012:529). They advised routine VL testing preswitch and 
(at least) at weeks 24 and 52 post-switch.  
  
4.4. Boosted-PI (LPV/r) to EFV substitution with prior NNRTI exposure:  
EFV-based cART is associated with lower rates of virologic failure than NVP-based 
regimens (Lowenthal et al, 2013: 1086); EFV seems to be better tolerated than NVP 
(Shubber et al, 2013) and has the additional benefit of allowing a once-daily dosing 
regimen in combination with ABC and 3TC (Scherpbier et al, 2007, Musiime et al, 
2010).   
NEVEREST 3, an open-label non-inferiority RCT, examined substituting LPV/r with EFV 
in virologically-suppressed children 3 to 5 years old receiving LPV/r-based treatment 
following NVP exposure during PMTCT (Coovadia et al, 2014 - unpublished). Although 
unpublished, results from the trial were presented at CROI in March 2014. The trial 
had 2 primary outcomes: viral rebound (any VL >50 copies/ml) and virologic failure 
(any confirmed VL > 1000 copies/ml). Children were randomised to switch to EFV 
(n=150) or stay on LPV/r (n=148) and were followed up for 48 weeks. The groups were 
comparable at randomisation with regard to age, gender, mean duration on cART and 
the NRTI backbone used. In the LPV/r arm, 28% of children experienced viral rebound 
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vs. 17% in the EFV arm (p=0.03). There was no difference in virologic failure between 
the LPV/r and EFV arms (2.0% vs. 2.6% respectively, p=0.68) by 48 weeks post-
randomisation. The non-inferiority analysis favoured EFV in terms of viral rebound and 
found EFV to be non-inferior to LPV/r in terms of virologic failure within the specified 
10% non-inferiority bound. Children in the EFV arm experienced mild, transient 
difficulty with sleep and experiencing nightmares. There was no significant difference 
between the arms of the trial in terms of CD4, growth, morbidity and mortality 
outcomes.  
4.5. Other simplification strategies in children:   
Foissac et al. (2011) examined once-daily LPV/r as a simplification strategy in a single 
centre observational study of 45 PI-experienced children in routine clinical care. This 
showed poorer virologic control compared to twice-daily dosing (57% vs. 74% 
maintaining VL <50 copies/ml, p<0.001). The KONCERT study (Lyall et al, 2014) was a 
Phase II/III randomised, open-label, multicentre, non-inferiority trial comparing once- 
vs. twice-daily LPV/r dosing. The median age of the 173 participants was 11yrs (IQR 
3.8 – 17.7yrs). All children were virologically-suppressed on LPV/r-based cART at 
screening. It did not demonstrate once-daily dosing to be non-inferior to twicedaily 
dosing. Thus once-daily dosing of LPV/r does not seem to be a feasible simplification 
strategy; at least not in older children.  
  
To address tolerability, avoidance of resistance and minimisation of side-effects, much 
work has recently been done on planned treatment interruptions (PTI) in children. 
Table 3 summarises 2 RCTs and a large prospective cohort. Treatment interruptions in 
the cohort study were unplanned, but it was included as being reflective of routine 
care. Reasons for treatment interruptions in the cohort study related to toxicity, 
virologic failure or drug resistance, adherence difficulties, clinical stability, palatability 
or tolerability issues and holiday periods. Other studies not included examined PTIs in 
children who were not virologically suppressed.  
  
As seen from these studies, PTIs may have a place in reducing time on cART in carefully 
selected and well monitored children. The optimal duration of cART prior to PTI is still 
poorly understood. There is no evidence showing benefit of unstructured, unplanned 
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5. SUMMARY  
  
The findings by McComsey and Vigano were very useful in establishing the virologic safety 
of substituting a PI with EFV in NNRTI-naïve HIV-infected children. Additionally, both 
studies showed improved adherence on EFV, which was well tolerated. The substitution 
led to significant improvements in serum lipid profiles.  
However, the participants in both these studies were relatively old (median age 12 and 10 
yrs, respectively), were heavily pre-treated but NNRTI-naive, were not on LPV/r or 
ritonavir-boosted PI regimens and were recruited from high-resource settings. Thus they 
differ quite markedly from children in our low-resource setting, who are often NVPexposed 
as part of PMTCT, are usually cART-naïve when started on LPV/r-based treatment and who 
tend to be younger.  
By the late 2000s, EFV was beginning to show superior efficacy over NVP. However, lower 
cost, availability of NVP-containing fixed-dose combinations and approval of NVP for use 
in children <3 years old made NVP the more frequently used NNRTI in low-resource 
settings.  
The NEVEREST study opted to re-use NVP (rather than using EFV) in HIV-infected children 
who had been exposed to NVP as PMTCT. The median age of trial participants was much 
lower (20 months at randomisation). This well-designed, appropriately-powered trial had 
virologic outcome, not toxicity or tolerability, as the primary outcome. The results are 
encouraging, although they do come with the caveat of VL testing pre- and repeatedly post-
substitution to ensure that children in whom the switch fails are identified promptly (and 
managed appropriately). HIV-resistance genotyping was further suggested in NEVEREST 2. 
Both tests are difficult in moderate-income-, but are likely unable to be performed in 
routine care in low-income settings. Additionally, inclusion of children with only sdNVP 
exposure limits the applicability to children currently in care who will likely have had 
considerably longer exposure to NVP for PMTCT.  Given the high incidence of tuberculosis 
in Sub-Saharan Africa both NVP and LPV/r may be difficult to use; EFV would be an easier 
drug in such settings.  
  
6. RECOMMENDATIONS  
  
6.1. Current research gaps in simplifying treatment for HIV-infected children  
NEVEREST 3 examined the simplification strategy of substituting LPV/r with EFV in 
children virologically suppressed on an initial LPV/r-based cART regimen. From this 
RCT the researchers concluded that the strategy was safe in children with prior NVP 
exposure for PMTCT and advocated consideration of such a strategy particularly in 
resource-limited settings.  
However, as trials do not mimic practise they produce good measures of efficacy but 
not of effectiveness. An observational study has the potential to augment the 
NEVEREST 3 trial findings in a resource-limited routine clinical setting. The proposed 
observational cohort study should be able to provide some evidence either to support 
or refute the NEVEREST 3 findings. Unfortunately, like NEVEREST 3, it will be limited 
RCHKIR001  Dissertation for MPH    PART B: LITERATURE REVIEW  
Part B |Page 12 of 16   
by the fact that participants will most likely have had only a single dose of post-partum 
NVP, with or without extended AZT. This will limit its generalisability to the group of 
young children in care born since 2010 who are most likely to have received extended 
NVP prophylaxis.  
  
6.2. Potential areas of future research aimed at simplifying treatment in HIV-infected 
children  
    
6.2.1. Review of infant prophylaxis in PMTCT programmes  
Should WHO Option B+ (WHO. 2013:41-50) be implemented satisfactorily the 
need for extended infant NVP prophylaxis may become obsolete. Stratifying 
vertical transmission risk, as is being done in some centres, is useful in deciding 
on appropriate infant prophylactic regimens. The current Western Cape 
Department of Health PMTCT Guidelines (Western Cape Government, 
2014:22-25) stratify risk, with extended NVP to low risk infants and the 
addition of 4 weeks of AZT to high risk infants. However, these 
recommendations still result in loss of the NNRTI class for treatment should 
the prophylaxis fail. Post-partum, sdNVP with ≥1 week of AZT (± 3TC) might be 
effective for low-risk infants, whilst NVP-based cART (with protection of the 
NVP tail) might be more effective than the current extended NVP for high-risk 
infants. Alternately, AZT-based regimens may be considered (Neubert et al, 
2013).  Provided the efficacy is non-inferior to extended NVP, these methods 
could potentially allow future use of the NNRTIs in children for whom PMTCT 
has failed.  
6.2.2. More palatable drug formulations and simpler dosing strategies  
Fixed-dose combinations are not readily available in child-suitable 
formulations. LPV/r syrup is poorly palatable, whilst the tablet formulation is 
bulky and difficult to swallow. There is promising data on the use of paediatric 
LPV/r mini-tab sprinkles (Musiime et al, 2014) which could overcome some of 
the challenges associated with LPV/r use.   
6.2.3. Understanding resistance and sequencing of cART in children  
As newer drugs are made available for use in children and as knowledge of 
the development of viral resistance patterns in infants and children expands, 
so the sequencing of ARVs may change, allowing children more options when 
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Background:    
The WHO recommends lopinavir/ritonavir-based (LPV/r) combination antiretroviral 
therapy (cART) as first-line for children <36 months old with the option to substitute 
LPV/r with a non-nucleoside reverse transcriptase inhibitor if virologic suppression is 
maintained. Few studies describe outcomes of this practice in routine settings. We aimed 
to compare outcomes of children commencing cART with LPV/r and substituting it with 
efavirenz once virologically suppressed and ≥36 months old (substitution group) with 
those remaining on LPV/r (stay group).   
Methods:      
All HIV-infected children at IeDEA-SA sites started on LPV/r-based cART from 2003-
2010 with virologic suppression at and follow-up beyond 36 months of age were 
included. None had >1 dose of nevirapine to prevent vertical transmission. Risk of HIV-
RNA >400 copies/ml after substitution or age 42 months was compared using a Cox 
proportional hazards model adjusted for predictors of virologic non-suppression.  
Results:      
Of 690 children included, 36 underwent substitution at a median age of 44.1 months. 
Groups were similar at baseline (age, anthropometry, clinical and immunological stage, 
HIV-RNA, cART regimen) and at 42 months / date of substitution. Thereafter, the 
probability of having an HIV-RNA >400 copies/ml was not significantly different 
between the substitution and stay groups, adjusted for other predictors of virologic 
rebound (adjusted HR 1.43, 95% CI 0.62; 3.30, p=0.401).   
Conclusions:     
In this cohort, virologic outcomes of children suppressed on LPV/r-based cART and 
subsequently changed to efavirenz were no worse than of those remaining on LPV/r. 
This may be an effective simplification strategy for carefully-selected children without 
prolonged postnatal nevirapine exposure.    
INTRODUCTION:  
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The World Health Organisation (WHO) recommends a lopinavir/ritonavir-based 
(LPV/r) combination antiretroviral therapy (cART) regimen for all HIV-infected 
children <36 months old irrespective of prevention of mother to child transmission of 
HIV (PMTCT) exposure. This is on the basis of better virologic suppression than 
nevirapine (NVP) (Palumbo et al. 2010; Violari et al. 2012). However, LPV/r syrup is 
poorly palatable, has food and refrigeration requirements, has concerning long-term 
metabolic side-effects and is difficult to co-administer with anti-tuberculosis (TB) 
treatment due to drug-drug interactions. Given these challenges, together with the need 
for excellent lifelong adherence to cART to achieve optimal benefits in children (Pham, 
2009), drug simplification strategies for children are an important area of research. 
Unlike LPV/r, the non-nucleoside reverse transcriptase inhibitors (NNRTI) NVP and 
efavirenz (EFV) are relatively cheap, easy to administer, have no refrigeration 
requirements, have a reasonable long-term side effect profile and can be administered 
once daily. Unfortunately high-level class resistance is easy to develop (Lockman et al, 
2007), and since NNRTIs form the basis of PMTCT, NNRTI resistance may limit 
treatment options in HIV-infected children who were exposed to NNRTIs antenatally, 
perinatally or through breastfeeding (Hunt et al, 2011; Micek et al, 2014; Zeh et al, 
2011).  Nevertheless, in 2013 the WHO added the option to substitute LPV/r with an 
NNRTI in children with sustained virologic suppression (WHO 2013:122). This 
conditional recommendation attempts to provide children with a simplified long-term 
regimen that avoids the challenges associated with prolonged LPV/r use. This 
simplification strategy is potentially cost-saving, regimen-sparing and more tolerable, 
with a better long-term side-effect profile (Penazzato et al, 2014; Vigano et al, 2005). 
Consequently, benefits should also exist in terms of adherence.   
The main evidence in support of the LPV to NNRTI substitution strategy has come from 
the Nevirapine Resistance Studies (NEVEREST). The NEVEREST 1 study included 
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children previously exposed to single-dose NVP during PMTCT who initially 
commenced LPV/r-based cART at <24 months of age and achieved virologic 
suppression within 12 months. Children were then randomized either to remain on 
LPV/r-based cART or to substitute LPV/r with NVP (Coovadia et al, 2010). NVP 
substitution was associated with favourable outcomes in the short term; although by one 
year post-substitution a significantly greater proportion of children in the substitution 
arm had failed virologically (confirmed viral load (VL) >1000 copies/ml). Routine VL 
monitoring post-substitution was recommended as a safety mechanism to identify 
failures timeously. This was also borne out in the long-term follow-up of the trial 
participants (Kuhn et al, 2012).      
In a second non-inferiority study (NEVEREST 3) HIV-infected children exposed to 
perinatal NVP as prophylaxis who were initiated on LPV/r based regimens at <24 
months old and had achieved virologic suppression were randomized either to continue 
LPV/r or have LPV/r substituted with EFV at age 3 to 5 years. The trial was powered to 
detect ≥10% difference in efficacy between the arms. The EFV arm showed better 
outcomes than the LPV/r arm in terms of viral rebound (i.e. single VL >50 copies/ml). 
In addition EFV was shown to be non-inferior to LPV/r in terms of virologic failure, 
defined as a confirmed VL >1000 copies/ml (Coovadia et al, 2014). Despite the 
promising results of NEVEREST 3, there is no published data on the outcomes of the 
LPV/r to EFV substitution strategy, as recommended by WHO, in routine care in 
resource-limited settings where children may not be monitored as rigorously as in a trial. 
The International epidemiologic Database to Evaluate AIDS Southern Africa (IeDEA-
SA) includes 8 sites in South Africa that have used the NEVEREST 3 strategy as part of 
routine clinical care. We therefore aimed to compare the virologic outcomes of  children 
aged ≥36 months who had achieved virologic suppression on a LPV/r regimen and then 
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either remained on a LPV/r regimen (stay group) or substituted LPV/r with EFV 
(substitution group) in the context of routine care.  
MATERIALS AND METHODS:   
Study design and setting  
We conducted a retrospective cohort study of HIV-infected children initiated on LPV/r-
based cART before 36 months of age at 8 South African IeDEA-SA sites between 2003 
and 2010. These sites have been described previously (Davies et al, 2009). Briefly, all 
but one are urban and most provide primary level care with some providing secondary 
or tertiary level care. South African National Department of Health guidelines (National 
Department of Health [NDOH], 2004; NDOH, 2010) were used by all sites to determine 
eligibility for cART, to initiate standard first-line cART regimens and to guide 
monitoring of safety and effectiveness. According to these guidelines children <36 
months old qualified for cART if they had a WHO clinical stage 3 or 4 condition, or met 
the stated criteria for severe immune suppression. After 2010 all infants <12 months old 
qualified for immediate cART.   
Throughout the study period a protease inhibitor-based first-line regimen was used in 
children <36 months of age, irrespective of NVP exposure. Between 2003-2008 children 
<6 months old or those receiving concurrent rifampicin-containing TB treatment were 
given ritonavir (RTV) alone as the protease inhibitor. This was replaced with LPV/r once 
>6 months old or on completion of TB treatment. After 2008 un-boosted protease 
inhibitors were not used; LPV/r was used in all children with additional ritonavir 
boosting if on concurrent rifampicin-containing TB treatment.  
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Until 2010 the nucleoside reverse transcriptase inhibitor (NRTI) backbone consisted of 
stavudine (D4T) or zidovudine (AZT) plus lamivudine (3TC).   
Once children reached 36 months of age clinicians at many of the IeDEA-SA sites 
elected, at their discretion, to substitute LPV/r with EFV. Sites were eligible for inclusion 
in our analysis if they had changed at least one virologically-suppressed child from a 
LPV/r- to an EFV-based regimen as a single class substitution where that substitution 
was not due to treatment failure or toxicity.  
Ethics considerations  
The data used for this analysis were anonymized and were obtained from individual 
IeDEA-SA sites, each of which holds Institutional Review Board (IRB) approval for 
contributing data to the IeDEA-SA collaborative analyses. The Universities of Cape 
Town (South Africa) and Bern (Switzerland) have IRB approval to curate the dataset 
and conduct analyses.  
Data collection  
Data was collected by participating sites. Anonymized data was transferred to the IeDEA 
Data Centres using a standard procedure for data transfer. From the database we 
extracted demographic details (age, gender), clinical stage and PMTCT information 
(where available) from the initial visit; anthropometry, CD4 and VL values throughout 




Definitions and outcome assessment  
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Substitution was defined as a single-class drug substitution, from LPV/r to EFV, in 
virologically-suppressed children ≥36 months old where the substitution was not due to 
failure or toxicity. Virologic suppression was defined as a VL <400 copies/ml in the 12 
months prior to turning 36 months old (stay group) or undergoing a substitution. 
Children who had undergone within-class substitutions at any time point for reasons of 
toxicity or the introduction of newer agents (e.g. abacavir (ABC) replacing D4T or AZT 
in both instances) were not excluded from the analysis.  
The primary outcome measure was the time to virologic non-suppression, defined as 
time from 42 months of age (stay group) or the date of substitution (substitution group) 
to first VL >400 copies/ml. Secondary outcomes included virologic failure (2 
consecutive VL measures >1000 copies/ml between 30 and 365 days apart and ≥6 
months after single drug substitution (substitution group) or 42 months of age (stay 
group)); transfer out (TFO) to another health facility for on-going management; loss to 
follow up (LTFU) (no visit for >270 days prior to database closure) and death.   
Statistical methods  
The characteristics of children at cART initiation and at either 42 months of age or at 
time of substitution in the stay and substitution groups were described and compared 
using Chi-squared or Fisher exact tests for categorical data; means, standard deviations 
and t-tests for normally distributed data and medians, inter-quartile ranges and Wilcoxon 
sum rank tests for skewed data. Logistic regression was used to examine associations 
between clinically relevant predictors of drug substitution and the probability of having 
undergone a LPV/r to EFV change. Time from age 42 months or point of substitution to 
virologic non-suppression was estimated using Kaplan Meier plots stratified by group 
and baseline clinical and immunological stage and compared using the log-rank test.  We 
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chose 42 months as the time in the stay group from which to compare outcomes with the 
substitution group based on a linear regression model predicting age of substitution. 
Since no covariates were significantly associated with substitution the intercept (44.5 
months) was used as a guide. Measuring outcomes from 36 months in the stay group 
would introduce bias in favour of the substitution group as, in practice, children 
substituted many months after age 36 months. A Cox proportional hazards model was 
used to examine the effect of changing from LPV/r to EFV after 36 months of age on 
the probability virologic non-suppression within the subsequent 24 months adjusted for 
other known, clinically relevant predictors of virologic failure. The model was built in a 
manual stepwise fashion.   
Potential explanatory variables for the outcome of virologic non-suppression were age, 
clinical stage and CD4 (absolute count and percentage) at cART initiation; perinatal 
NVP exposure; CD4 count and weight-for-age z-score (WAZ) at 42 months of age or at 
point of substitution; and viral blips whilst on cART prior to 36 months of age. A viral 
blip was defined as an isolated VL >1000 copies/ml which subsequently returned to 
<400 copies/ml at the next measurement (conducted within 24 months) with no change 
in cART regimen. These covariates were considered for inclusion in the final Cox model 
if they were associated with time to virologic failure in the univariate analysis with 
p≤0.20. Perinatal NVP exposure was excluded due to a paucity of PMTCT related data. 
Models were compared using Aikaike’s information criterion (AIC) or the log-likelihood 
ratio test for non-nested and nested models, respectively. The substitution variable was 
then added to the final model and interpreted.  
Data was analysed using STATA®/IC 11.1 for Windows Data Analysis and Statistical 
Software (StataCorp LP, 4905 Lakeway Drive, College Station, TX 77845, USA).  
RESULTS  
RCHKIR001  Dissertation for MPH    PART C: JOURNAL MANUSCRIPT  
Part C | Page 9 of 22   
Description of the stay and substitution groups  
Of 690 eligible children (Figure 1), 36 (5.2%) had LPV/r substituted with EFV at a 
median age of 44.1 months (IQR 40.9; 51.8). At initiation of cART the stay and 
substitution groups did not differ significantly (Table 1) in terms of median age (17.6 vs. 
15.3 months), pre-cART CD4 percentage (13.9 vs. 13.0%), weight-for-age z-score (-
2.34 vs. -2.56) or WHO clinical stage 3 or 4 (89.8% vs 80.8%). A cART backbone of 
stavudine plus lamivudine was used in >94% children in both groups. Data about 
PMTCT exposure was poorly captured with 73.2 vs. 66.7% of children in the stay and 
substitution groups, respectively, having unknown PMTCT status. However, in the 
substitution group no child was known to have had NVP (vs. 18/654 children in the stay 
group) and only 16.7% were known not to have received any PMTCT intervention (vs. 
9.0% in the stay group, p=0.374). At 36 months of age—the point at which children 
became potentially eligible for single-class drug substitution—the groups were still 
comparable. Median CD4 percentage (29.3 vs. 28.6%) and weight-for-age zscores (-0.88 
vs. -0.67) remained similar in the stay and substitution groups, respectively. Given the 
eligibility criteria, all children in both groups had a VL <400 copies/ml at 36 months of 
age.  
At either 42 months of age or at the point of substitution—the baseline time-point for 
measuring the primary time-to-event outcome—the groups were not significantly 
different (Table 2). However, 318 (48.6%) children in the stay group experienced at least 
one viral blip before 36 months of age compared with 10 (27.8%) in the substitution 
group (p=0.015).  By this time the use of abacavir had increased from 1% initially to 
5.5% in each group, with stavudine use having dropped accordingly, in  
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keeping with wider availability of abacavir for use in first-line in South Africa from 2010 
onwards.  
All children were followed up for at least 6 months after substitution (substitution group) 
or turning 42 months old (stay group). Median observation time from cART initiation to 
last recorded visit tended to be shorter in the stay group (52.4 vs. 60.1 months, p=0.065). 
However, median observation time from 42 months old in the stay group was 24.4 
months (IQR 18.1; 31.7) which was similar to the median observation time from date of 
substitution of  25.8 months (IQR 15.1; 34.2) in the substitution group.  
Factors associated with single-drug substitution  
Factors considered a priori to be clinically relevant in deciding to institute a singledrug 
substitution were PMTCT exposure, immune recovery (as determined by CD4 measure) 
and favourable clinical response to cART (as determined by weight-for-age z-score) at 36 
months of age, and whether or not the child had experienced a viral blip on cART before 
36 months of age. Experiencing a viral blip (unadjusted OR 0.34, 95% CI 0.15; 0.78, 
adjusted OR 0.34, 95% CI 0.15 - 0.79) and an unfavourable weight-forage z-score at 36 
months (adjusted OR 1.34 per 1 z-score increase, 95% CI 0.96; 1.80) were associated with 
not undergoing a single-drug substitution. In this cohort PMTCT exposure was excluded 
due to paucity of data whilst CD4 measure (percentage or absolute count) at the time of 
eligibility for substitution was not significantly associated with undergoing a substitution.   
Outcomes after substitution   
Three children (0.43%) died after 42 months of age; all in the stay group. More children 
in the stay group were transferred to other facilities for on-going care (42.5% vs. 25.0% 
in the substitution group (p=0.039)). The proportion of children lost to follow-up was 
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twice as high in the substitution group, although this was not statistically significant (11.1 
vs. 5.4%, p=0.139).  
Overall 66 (9.6%) children experienced virologic failure; 64 (9.8%) in the stay and 2  
(5.6%) in the substitution group (p=0.565). However, of the children who had one VL 
>1000 copies/ml only 67.5% vs. 67.7% in the stay and substitution groups had a repeat 
VL measure before the end of follow-up.   
The incidence rate ratio of the time-to-event endpoint of first VL >400 copies/ml was 
1.03 (95% CI 0.43 to 2.08) in the substitution relative to the stay group. The following 
clinically relevant variables were associated with time to first VL >400 copies/ml after 
42 months of age/substitution: duration on cART prior to 42mo /substitution (adjusted 
HR 0.96 per extra month on cART, 95% CI 0.93; 0.98, p=0.002), weight-for-age zscore 
at initiation of cART (adjusted HR 0.87 per 1 z-score increase, 95% CI 0.78; 0.98, 
p=0.022), and having experienced at least one viral blip before 36 months of age 
(adjusted HR 2.26, 95% CI 1.52; 3.36, p<0.001). Having undergone a LPV/r to EFV 
substitution was not associated with time to first VL >400 copies/ml after 42months of 
age/ post-substitution (unadjusted HR 1.02, 95% CI 0.44; 2.32) even when adjusted for 
the variables above (adjusted HR 1.43, 95% CI 0.62; 3.30, p=0.401) (Table 4).   
Of the 36 children who were switched to EFV, 7 (19.4%) were changed back to LPV/r 
within a median period of 5.5 (IQR 2.7 – 6.6) months. There was no reason recorded for 
reinstitution of LPV/r in 4 of the children, while 2 were recorded as having virologic 
failure and one had a VL of 12 000 copies/ml after 2 months on EFV. Four of these 
children had experienced at least one blip prior to 36 months of age; whilst none of the 
children successfully remaining on the switched regimen had experienced any such 
blips.  In 5/7 children the return to LPV/r was virologically successful, one child had no 
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subsequent VL measurement whilst on the study and cART was stopped in one child 
due to non-adherence. Six of the seven children came from the same site (supplementary 
material: Table 5).    
DISCUSSION  
In our cohort study, conducted in the context of routine, public-sector care in South 
Africa, we found no difference in the probability of virologic non-suppression between 
children ≥36 months of age who substituted LPV/r with EFV compared to those who 
remained on a LPV/r-based cART regimen. This finding concurs with the results of the 
NEVERST 3 trial, suggesting generalizability beyond the clinical trial setting. We also 
found that children who had experienced viral blips were both less likely to undergo 
substitution and more likely to experience virologic non-suppression irrespective of 
whether they were substituted or not.   
In this cohort, 496 (87.3%) children were severely immune suppressed prior to cART 
initiation, 540 (89.4%) of those with a recorded baseline clinical stage had symptomatic 
HIV infection with 320 (58.2%) children being either severely (WAZ ≤-3) or moderately 
(WAZ ≤-2) underweight for age (Table 1). By 36 months of age the children had 
responded well to cART, with CD4% increasing and WAZ improving to within near-
normal values (median WAZ -0.82; IQR -1.60 to -0.08). This excellent response in growth 
is likely due to the young age of the cohort (McGrath et al, 2011). Moreover, since 
nutritional status improves with control of viral replication in children, an improved WAZ 
likely reflects both good adherence and improved overall health (Tukei et al, 2013). This 
would probably explain why, at 36 months of age, a more favourable WAZ was positively 
associated with the probability of undergoing a LPV/r to EFV substitution. Conversely, 
viral blips imply periods of sub-optimal or variable adherence to cART. In the study, 
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children who experienced viral blips prior to 36 months of age were less likely than those 
who hadn’t to undergo single-drug substitution. Thus, clinicians seem to have chosen 
children with a good clinical response and a record of good adherence as candidates for 
simplification. This is likely to have introduced selection bias in favour of the substitution 
group. The finding that 7 (19.4%) children were switched back to LPV/r within a very 
short period after the substitution is concerning. Given the short time period one could 
assume that sideeffects or tolerability may have played a role. It is also notable that more 
than half (4 of 7) the children who were changed back to LPV/r after substitution had 
experienced viral blips prior to substitution, suggesting that substitution may not be an 
optimal strategy in patients with poor adherence to their primary regimen. Notably, the 2 
children changed back to LPV/r due to documented failure after the substitution both had 
evidence of variable adherence on their initial regimen, with viral blips. Reassuringly, 
however, 5 of the 7 children (71%) re-suppressed on LPV/r.  
A child’s exposure to NNRTIs during the peripartum/neonatal period may be a critical 
factor in deciding about simplifying to an EFV-based regimen, given the low genetic 
barrier to high level NVP resistance and the cross-resistance that occurs between NVP 
and EFV. A limitation of this study was the paucity of accurate PMTCT data. Overall 
72.9% of children had PMTCT history recorded as being unknown, 9.4% were known 
not to have received any PMTCT intervention, whilst only 2.6% had the actual drugs 
and duration of PMTCT regimens recorded. We were therefore unable to determine 
whether PMTCT exposure influenced clinicians’ decision to substitute therapy or had 
an impact on virologic non-suppression after substitution/42 months of age.  Although 
this is a weakness of the study, it probably reflects the reality clinicians often face, i.e. 
limited or inaccurate history regarding PMTCT, although with increasing PMTCT 
coverage and cART initiation at younger ages following the CHER trial findings (Violari 
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et al, 2008) and WHO 2010 guidelines (WHO, 2010), knowledge of PMTCT exposure 
is likely to be better known and recorded. It is important to remember that throughout 
the study period infants would not have received more than a single dose of NVP post-
partum, which may have been given with a 7 or 28 day course of AZT, as per the 
prevailing PMTCT guidelines. Furthermore, EFV-based cART for all pregnant mothers 
from 14 weeks of gestation to (at least) the end of breastfeeding was also not practised 
during the study period. This study’s results would thus not be applicable to current 
children; except those known to have had no PMTCT exposure.   
Other limitations included paucity of data around adherence (VL blips were considered 
a proxy for poor adherence), social factors, other comorbidities and side-effects.  
NEVEREST 3 reported a high but transient incidence of neuropsychiatric symptoms 
after substitution to EFV. Lack of data on adverse events precluded us from fully 
assessing the safety of the strategy.   
It seems clinically significant that LTFU was twice as high in the substitution group, but 
the reasons are unclear. Likewise, the difference in TFO of patients between groups may 
have introduced selection bias. However, the groups were followed up for a relatively 
equivalent duration post-substitution/42 months of age. This is reassuring as the finding 
of no significant difference in time to viral failure between the groups is unlikely to be 
due to differential follow-up time. Sample size was smaller than anticipated in our initial 
sample size and power calculations, thus increasing the chance of a type 2 error. The 
number of children undergoing a LPV/r to EFV substitution was also small, thus 
uncertainty exists around our finding of no significant difference in virologic outcomes 
between the groups.  
CONCLUSION  
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In this cohort of South African HIV-infected children on LPV/r-based cART in a routine 
care setting, substitution of LPV/r with EFV after 36 months of age in those who 
achieved and maintained virologic suppression was not associated with an adverse 
virologic outcome, supporting findings of the NEVEREST III randomised-controlled 
trial. However, this cohort was not exposed to more than a single postpartum dose of 
NVP as infant prophylaxis, hence this treatment simplification strategy may not be 
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1 Introduction   
1.1 General remarks  
  
• This document provides guidance on the preparation of data tables for the 
transfer of data for the IeDEA Southern Africa Collaboration.  
• It is requested that each clinic prepares ten separate tables with the new data, 
as described in detail below. While 6 of these tables should be submitted by all 
sites, tables 7 -10 will only be applicable to certain sites (see below).   
• The tables can be sent in the format that is most convenient for the site, 
including MS Excel, MS Access, ASCII etc. Please contact the IeDEA data 
manager if you have any queries.   
• It is appreciated that for some clinics it may be easier to send their data as 
they stand (for example in Excel) and to leave the data management and 
preparation of the ten tables to the data centre. This is not a problem, but 
it is requested that a separate document be included with a list of the 
variables in the dataset and brief descriptions/definitions.   
• It is accepted that there will be missing data for some patients, and even entire 
missing tables from some sites who simply do not have that data in electronic 
format.   
• It is requested that for security purposes, data tables be encrypted and 
compressed with WinZip 9 or higher using the AES encryption algorithm prior 
to sending.  The encryption password (minimum of 10 characters long, 
including upper/lower case, numbers and special characters) should be 
communicated to the relevant data centre contact person by fax or by 
telephone.    
• Please ensure that the dataset has been stripped of personal identifying 
information prior to sending.  
• Please include a unique anonymous identifier for each patient (PATIENT) for 
cross-reference with your own database. It can be the identifier you are using 
or a special identifier you create for IeDEA Southern Africa. This 
anonymization key must be maintained by the site under secure conditions.   
• Sites treating children should please send the date at which they changed from 
using the WHO 3-stage clinical staging system to the 4-stage clinical staging 
system.  
• Thank you very much for your contribution to this collaborative project!  
  
1.2 Inclusion criteria for patients  
  
Please include all patients with the following characteristics:   
  
• Documented HIV-1 infection   
• Patients in care at the facility for whom the date of first visit at the facility is 
known exactly.   
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Notes:  
• Where possible, it is intended that data be transferred on HIV-infected patients 
followed-up at the facility irrespective of whether or not they received highly 
active antiretroviral therapy (HAART).  
• When transferring data just on patients who received HAART, it is preferable 
to include patients irrespective of whether or not they were exposed to 
antiretrovirals before the recorded HAART start date. In other words 
treatmentnaïve and treatment-experienced patients are included.   
• Sites should send all information on all patients (adults and/or children) in a 
single dataset. For adult patients (those whose first visit at your facility was 
after their 16th birthday) the paediatric specific fields (highlighted in blue) do 
not need to be completed (i.e. enter code 88 – not applicable). Paediatric 
specific fields must be entered as completely as possible for all patients whose 
first visit at your facility is before their 16th birthday even if their follow-up 
extends beyond the age of 16 years.   
• Some patients will have been in care at another facility prior to commencing 
care at your facility. These patients should be included in the dataset, noting 
against the relevant field that they have been transferred in. All treatment and 
opportunistic infection (OI) history prior to commencing care at the facility 
should be reconstructed as far as possible and entered in the appropriate tables, 
with unknown codes for dates of start and end date of OIs/antiretroviral drugs 
where necessary.  
  
1.3 Dates  
  
• The term baseline will not be used as this creates confusion. We will rather 
make use of a set of key dates that will be entered into the first table, the 
PATIENT table. These are:  
  
Variable name  Definition of key date  
FRSVIS_DMY  Date of first visit at your facility  
HIVP_DMY   
(HIVP_Y (year) and HIVP_M (month) 
if exact date unknown)  
Date of first positive HIV-1 test  
HAART_DMY  Date of HAART initiation  
  
• For all fields that require a date, the precise date should be entered in the 
format   
dd-mm-yyyy if it is known. If the precise date is not known, the month and 
year should be entered separately as far as possible in the separate dedicated 
fields provided for these, and the precise date field should be left blank.   
• If month or both the year and month are unknown, the precise date field should 
be left blank and unknown codes should be entered into the year field (9999) 
and the month field (99) as appopriate.    
• For certain date fields a precise date is obligatory e.g date of first visit at your 
facility (FRSVIS_DMY) and date of HAART initiation (HAART_DMY). In 
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patients who commenced HAART at another facility, if the precise date of start 
of HAART cannot be estimated reasonably accurately, the patient should be 
entered as treatment experienced and the date of first visit at your facility will 
be regarded as the date of start of HAART.  
1.4 Definitions   
  
• HAART is defined as treatment with a combination of at least three drugs from 
any class or classes.   
• “Treatment experienced” is defined as previous exposure to any antiretroviral 
drug for at least 30 days, excluding exposure for prevention of mother to child 
transmission (PMTCT) or post-exposure prophylaxis (PEP).   
  
1.5 Standard codes  
  
Certain codes will appear repeatedly in a number of lists for coded fields. In this 
instance, the same codes/coding format will be used in all fields where these codes 
appear as follows:  
  
Codes  Description  
0  No  
1  Yes  
90  Other  
95  Not ascertained/Not collected at this facility  
99  Unknown despite attempting ascertainment   
88  Not applicable  
  
1.6 Data tables  
  
For each clinic, the following five to ten data tables or files should be prepared, 
depending on data availability.   
  
• Tables 1 to 5 are required by all sites.   
• Table 6 (LINKAGE DATA) is required only for sites that record information 
on families  
• Table 7 (PREGNANCY) is required only for sites that record information on 
pregnancy electronically.   
• Table 8 (PAR HEALTH) is required only for patients who commence care 
before their 16th birthday.   
• Table 9 (TB) is required only from sites that record detailed information on 
episodes of tuberculosis electronically.   
• Table 10 (TRIAL) is required only for sites where patients may be enrolled on 
clinical trials or research studies apart from cohort analyses of routinely 
collected data.   
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• In addition, a table summarising with information on the overall cohort or 
“meta-data” for the transfer, should be included with all transfers.  
   
1. PAT (Patient data): A table containing socio-demographic data on patients, 
clinical characteristics at start of HAART in HAART-treated patients, as well  
as information on the outcomes of patients. One line will correspond to one 
patient. In other words, each patient will appear only once in this table. We 
propose that this table is called PAT.    
2. LAB (Laboratory data at baseline and follow-up): This is a single table 
containing all laboratory data: CD4, HIV viral load, and all other laboratory 
tests.  One line will correspond to one laboratory result. In other words, most 
patient will have multiple records in this table. We propose that this table is 
called LAB.   
3. ART (Antiretroviral treatments): A table with the data on all antiretroviral 
drugs that a patient has received or been exposed to including PMTCT (both 
exposure to mother as well as infant peri- or post-natal) or post-exposure 
prophylaxis. This includes treatment received at your facility and at other 
facilities.  The table will contain one line for each separate drug, with different 
fields for the drug name (code), the prescription start dates and stop dates.  
Most patients will have numerous records in this table.  The drug history of 
patients who commence care at your facility but have previously been treated 
at another facility should be reconstructed and entered into this table as far as 
possible. We propose that this table be called ART.  
4. OI (Opportunistic Events): A table with the information on all opportunistic 
infections or incident HIV-associated diagnoses. One line will correspond to 
one clinical event with different fields for the event type (code), the start dates 
and stop dates. It is anticipated that stop dates will often not be known. In other 
words, some patients will have more than one record in this table and some 
may have no records in this table. History of opportunistic events occurring 
prior to commencing care at your facility should be reconstructed as far as 
possible.  We propose that this table be called OI.  
5. VIS (Visit data): A table containing information on all clinical visits 
(including the first visit at your facility). One line will correspond to one visit.  
Most patients will have more than one record in this table. We propose that this 
table be called VIS.  
6. LINK (Linkage data): A table containing information on family members 
(partners, children and siblings) also receiving HIV care either within your 
cohort or at another site. All family members receiving HIV care should be 
included whether they are receiving care at an IeDEA collaborative site or at a 
non-IeDEA site. One line will correspond to one family member receiving HIV 
care. In other words, some patients will have more than one record in this table 
and some may have no records in this table. We propose that this table is called 
LINK.   
7. PREGNANCY (Pregnancy data): A table containing information on all 
pregnancies, including spontaneous abortions/miscarriages and terminated 
pregnancies, and their outcomes. One line will correspond to one pregnancy. 
Multiple pregnancies will each have a record in the table, with the outcome of 
the relevant foetus recorded. Some patients will have more than one record in 
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this table, while others (including all males and children less than 10 years) 
will have no records in this table. We propose that this table be called  
PREGNANCY.  
8. PAR_HEALTH (Parental health): A table with information on parental 
health status. This table is only required for sites sending data on patients 15 
years old and younger at their first visit to the facility.  This table is linked to 
the visit table, so ideally there is an update on parental health status at every  
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visit. Alternatively, this table should be filled in at least once, either for the first 
visit at your facility or the date of start of HAART.   
9. TUBERCULOSIS (Tuberculosis data): A table with information on all 
episodes of tuberculosis (TB). This table is only for sites that record detailed 
information on TB episodes. Sites that do not collect detailed information on 
TB episodes should enter the TB episodes in the OI table. One line will 
correspond to one TB episode. In other words, some patients will have more 
than one record in this table and some may have no records in this table. We 
propose that this table be called TB.  
10. TRIAL (Enrolment in trials): A table with information on any trial or 
research study (apart from cohort analysis of routinely collected data) on which 
a patient is enrolled.  This table is only for sites running trials or research 
studies. One line will correspond to one trial/research study on which the 
patient is enrolled. In other words, some patients will have more than one 
record in this table and some may have no records in this table. We propose 
that this table be called TRIAL.  
11. MET (Meta-data):  A table comprising key characteristics of the data that is 
transferred.  
  
2 Variables to be included in core tables  
2.1 Socio-demographic characteristics and outcomes (PAT table)  
  
Table 1 below details the data that should be included in PAT table.   
  
The patient identification variable (PATIENT) must be unique, and it cannot be 
missing in any of the tables. This field must contain a unique and anonymous 
patient identifier; the field must NOT contain their name or any other identifying 
information. It is up to the local collaborator to maintain the key for linking the 
unique patient identifier with the patient.  
  
Table 1 – Variables to be included in PAT table  
Name  Format and definitions  Description  
PATIENT  
Free (numerical or 
alphanumerical)  Unique, anonymous, patient identifier  
COHORT  Text  Text field identifying the cohort  
FACILITY  Text  
Text field identifying particular clinic 
within cohort, if more than facility  
within the cohort  
BIRTH_DMY  DATE (yyyy-mm-dd)  
Date of birth   
Enter exact date in this field if known.  
If unknown leave blank and enter 
month and year as far as possible in 
fields below.  
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BIRTH_Y  
Numeric (for example 1960)  
  
9995 = Not ascertained  
9999 = Unknown despite 
attempting ascertainment  
Year of birth  
 
BIRTH_M  
Numeric (for example 8)  
  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Month of birth  
GENDER  
Numeric with codes:  
  
1 = Male  
2 = Female  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Sex / gender of patient  
FRSVIS_DMY  DATE (yyyy-mm-dd)  
Date of first visit at facility   
(Note: This date must be entered 
exactly)  
ENTRY  Numeric with codes (see List 1)  Mode of entry to your facility  
ENTRY_OTHER  Text  
Details of other mode of entry not listed 
in List 1  
MODE  Numeric with codes (see List 2)  Most probable mode of  HIV 
transmission   
HIV_TYPE  
Numeric (for example 1)  
  
1 = HIV-1  
2 = HIV-2  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Field to distinguish HIV-1 from HIV-2  
HIVP_DMY  DATE (yyyy-mm-dd)  
Date of first positive HIV test  
Enter exact date in this field if known.  
If unknown leave blank and enter month 
and year as far as possible in fields 
below.  
HIVP_Y  
Numeric (for example 2001)  
  
9995 = Not ascertained  
9999 = Unknown despite 
attempting ascertainment  
Year of first positive HIV-1 test  
HIVP_M  
Numeric (for example 8)  
  
95 = Not ascertained   
99 = Unknown despite 
attempting ascertainment  
Month of first positive HIV-1 test  
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HIV_TEST  
Numeric with codes (IeDEA SA 
codes)  
  
1 = Presumptive diagnosis  
2 = Serology  
3 = PCR  
4 = P24  
5 = Rapid test  
90 = Other  
95 = Not ascertained  
99 = Unknown despite  
Type of test used for diagnosis   
 




0 =  Never started HAART  
1 =  Started HAART   
Conditional:  




DATE (yyyy-mm-dd)  
  
  
Date of HAART initiation   
(minimum 3 drugs together)  
Note: This date must be entered exactly. If patient 
commenced HAART at another facility and the 
exact date is not known, the patient should be  
entered as “Treatment experienced” in the EXP_Y 
field below and the first visit at your facility will 
be used as the start of HAART date.   
FHV_STAGE_WHO  
Numeric with codes:  
  
1 = Stage I  
2 = Stage II  
3 = Stage III  
4 = Stage IV  
88 = Not applicable  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Clinical WHO stage (I to IV) at time of 
starting HAART  
(Enter 88 patients who have not 
commenced HAART)  
FHV_SDI_1  
Text (for example PCP - see List  
3)  
  
88 = Not applicable  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Stage defining illness-1 at time of 
starting HAART.  
(Enter 88 patients who have not 
commenced HAART)  
Note: At least FHV_S_SDI_1 should be 
completed in patients commencing  
HAART; A maximum of 4 stage  
defining illness can be entered in the 4  
fields provided. There is no specific 
ordering to the entering of stage 
defining illnesses.   
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FHV_SDI_2  
Text (for example PCP - see List  
3)  
  
0 = No further stage defining 
illness  
88 = Not applicable  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Stage defining illness-2 at time of 
starting HAART.  
(Enter 88 patients who have not 
commenced HAART)  
  
FHV_SDI_3  
Text (for example PCP - see List  
3)   
  
0 = No further stage defining 
illness  
88 = Not applicable  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Stage defining illness-3 at time of 
starting HAART.  
(Enter 88 patients who have not 
commenced HAART)  
  
FHV_SDI_4  
Text (for example PCP - see List  
3)   
  
Stage defining illness-4 at time of 
starting HAART.  
(Enter 88 patients who have not  
RCHKIR001  Dissertation for MPH   PART D:  APPENDICES   
Part D: Page 12 of 50   
 
 0 = No further stage defining 
illness  
88 = Not applicable  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
commenced HAART)  
  
EXP_Y  
Numeric with codes:  
  
0 = No (No previous ARV  
experience )  
1 = Yes (Treatment 
experienced, drug history known 
and recorded in ART table)  
2 = Yes (Treatment 
experienced, drug history not 
known)  95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Patient is treatment experienced prior to 
starting HAART (HAART_DMY) ?   
Experienced = Any ARV drug (single 
or dual therapy) for at least 30 days 
before starting HAART (PMTCT  
regimen and PEP excluded).  This field 
can also be used in patient has  
interrupted ART and prior ART start 
date unknown.  
This should be entered for all patients 
even those who have not commenced 
HAART.   
MTCT_Y  
Numeric with codes:  
  
0 = No (No MTCT 
exposure )  
1 = Yes (MTCT 
exposed, drug history 
reconstructed  and recorded in 
ART table) 2 = Yes (MTCT 
exposed, drug history not 
reconstructable)    
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Patient exposed to MTCT drugs (either 
mother during pregnancy or infant peri-  
or post-natally) prior to start of HAART  
(HAART_DMY)?  
This should be entered for all patients 
even those who have not commenced 
HAART.  
PEP_Y  
Numeric with codes:  
  
0 = No (No PEP 
exposure)  
1 = Yes (PEP exposed, 
drug history reconstructed  
and recorded in ART table) 2 
=Yes (PEP exposed, drug 
history not reconstructable)    
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Patient exposed to post-exposure 
prophylaxis (PEP) drugs prior to start of  
HAART (HAART_DMY)?  
This should be entered for all patients 
even those who have not commenced 
HAART.  
TB_FHV  
Numeric with codes  
  
0 = No  
1 = Yes  
88 = Not applicable  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Patient was on treatment for TB at start 
of HAART (HAART_DMY)  
(Enter 88 patients who have not 
commenced HAART)  
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WKS_TB_FHV  
Numeric (for example 8)  
  
88=Not applicable  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment   
Duration in weeks since start of TB 
treatment when HAART was  
commenced in  patients with TB at start 
of HAART   
(Enter 88 for patients who have not 
commenced HAART or who did not 
have TB at start of HAART)  
 
PREG_FHV  
Numeric with codes   
  
0 = No  
1 = Yes  
88 = Not applicable  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Pregnant at start of HAART  
(Enter 88 for men and children <10 
years old AND all patients who have not 
commenced HAART)  
METHOD_INTO_ART  
Numeric with below codes  
  
0 = New  
1 = Transfer  in  
88= Not applicable  
Method into ART at current clinic:  
If patient is new to ART or considered 
treatment experienced and re-starting  
ART at your clinic (please see EXP_Y) 
then they are ‘New’.  
If patient is coming to you clinic on 
ART then patient is considered a 
‘transfer in’.  
(Enter 88 for all patients not yet on  
ART)  
TRANSFER_IN_DATE  DATE (yyyy-mm-dd)  
Date of first visit in your clinic   
(Leave blank if patient is not considered 
a transfer in)  
FROM_LOCATION  
Numeric with below codes  
  
0 = Within province  
1 = From other province  
2=  From other country  
88= Not applicable  
This is the location  the patient 
transferred from while on ART.  
(Enter 88 for all patients not yet on  
ART and for all patients who are not 
considered a ‘transfer in’)  
LAST_CONTACT_DMY  DATE (yyyy-mm-dd)  
Date of last contact  
Note: This date must be entered exactly.  
LAST_CONTACT_T  Numeric with codes (See List 4)  Type of last contact  
OUTCOME  Numeric with codes (See List 5)  
Outcome including death and loss to 
follow-up  
OUTCOME_DMY  DATE (yyyy-mm-dd)  
Date of outcome   
(Leave blank if outcome is Alive [in 
care] or   
Alive [not in care])   
OUTCOME_Y  
Numeric (e.g. 2004)  
  
8888 = Not applicable or exact 
date of outcome entered above  
9995 = Not ascertained   
9999 = Unknown despite 
attempting ascertainment  
Year of outcome  
Enter 8888 for patients who have not 
died, or if exact date of outcome entered 
above.  
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OUTCOME_M  
Numeric (e.g.12)  
  
88 = Not applicable or exact date 
of outcome entered above  
  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
  
Month of outcome  
Enter 88 for patients who have not died, 




DEATH_C1  Numeric with codes (see List 6)    
Cause of death :  
Enter 88 for patients who have not died  
 
  Note : There are 3 fields for 3 causes of 
death to be entered in no specific order.  
If an HIV-related cause of death is 
recorded, please ensure that the  
condition is recorded appropriately in 
the OI table.    
  
Nature of contribution of cause: For 
each cause of death, please 
characterise the contribution of the 
specific cause.  
DEATH_N1  
Text with following codes:  
I = Immediate cause  
U = Underlying cause/condition  
C = Contributing cause  
N = Not available  
  
DEATH_C2  Numeric with codes (see List 6)    
DEATH_N2  
Text with following codes:  
I = Immediate cause  
U = Underlying cause/condition  
C = Contributing cause  
N = Not available  
  
DEATH_C3  Numeric with codes (see List 6)    
DEATH_N3  
Text with following codes:  
I = Immediate cause  
U = Underlying cause/condition  
C = Contributing cause  
N = Not available  
  
CAREG  Numeric with codes (see List 7)  
Primary caregiver at start of HAART  
(HAART_DMY)  
(paediatric patients only – enter 88 for 
adult patients)  
DISCL_CG  Numeric with codes (see List 8)  
Person informed of the HIV status of 
the child  
(paediatric patients only – enter 88 for 
adult patients)  
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DISCL_CHILD  
Numeric with codes  
  
0 = No  
1 = Yes  
2 = In process  
88 = Not applicable (adult  
patient)  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Was the child informed of his/her status 
at HAART_DMY?  
(paediatric patients only - enter 88 for 
adult patients)  
DELIV_M  
Numeric with codes  
  
10 = Vaginal, spontaneous  
11 = Vaginal, forceps  
12 = Vaginal, vacuum  
20 = Caesarean section – 
primary/elective (before onset of 
labour and rupture of 
membranes)  
Mode of delivery   
(paediatric patients only - enter 88 for 
adult patients)  
 21 = Caesarean section – 
emergency  
22 = Caesarean section – 
type  
unknown  
88 = Not applicable  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
 
WEIGHT_BIRTH  
Numeric (e.g 3.20)  
88 = Not applicable  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Weight at birth in kg   
(paediatric patients only - enter 88 for 
adult patients)  
BRSTFD  
Numeric with codes  
  
10 = breastfeeding, exclusive  
11 = breast-feeding, exclusivity  
unknown   
12 = mixed feeding  
20 = Formula feeding  
88 = Not applicable  
95 = Not ascertained  
99 = Unknown, despite 
attempting ascertainment  
Main infant feeding option after birth  
(paediatric patients only - enter 88 for 
adult patients)  
BRSTFD_ED  DATE (dd-mm-yy)   
Date of cessation of breast feeding if 
applicable  
Leave blank if not applicable, child still 
being breastfed, date not known, or 
child not breastfed at all.  
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BRSTFD_EST_DUR  
Numeric (e.g. 2)  
  
77 = still breast-feeding, ED 
unknown  
88 = Not applicable  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Estimated duration of breastfeeding in 
months in children who are exclusively 
breastfed or mixed fed.  
(paediatric patients only - enter 88 for 
adult patients)  
Enter 88 if child still being breastfed or 
child not breastfed at all.  
  
List 1 - Codes for mode of entry (ENTRY)   
Code source: IeDEA SA codes  
Table name: LU :PAT :ENTRY  
  
Codes  Mode of entry  
1  PMTCT program  
2  Diagnosis testing during hospitalization  
3  Diagnosis testing during consultation  
4  Orphans programs  
5  Family diagnosis  
6  TB program  
7  General HIV service clinic  
8  Self-referral with known diagnosis  
90  Other  
95   Not ascertained  
99  Unknown despite attempting ascertainment  
  
List 2 - Codes for mode of infection (MODE)  
Code source: Based on HICDEP codes; new codes denoted by *  
Table name: LU_mode  
  
Codes  Mode of infection  
1  Homo/bisexual man   
2  Injecting drug user  
3  Homo/bisexual man + injecting drug user (1 + 2)  
4  Haemophiliac  
5  Transfusion, non-haemophilia related  
6  Heterosexual contact  
7  Heterosexual contact + Injecting drug user (6 + 2)  
8  Perinatal  
90  Other  
95*   Not ascertained  
99  Unknown despite attempting ascertainment  
  
List 3 - Disease codes for FHV_SDI (PAT table) and OI_ID (OI table)  Code 
source: Based on HICDEP codes; new codes denoted by *  
Table name: LU:DIS  
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Note that this is a common list of HIV-associated conditions for capturing incident opportunistic infections and 
HIV-associated conditions, as well as stage-defining conditions in adults and children.  Where duration or 
recurrence is required for a condition to be stage defining, the event columns have a zero to exclude them from 
lookups of incident conditions. Where conditions are not stage defining, the stage-defining columns for children and 
adults have zeros to exclude them from lookups of stage-defining conditions.  
  














ANGC*  Angular cheilitis  2  2  1  1  1  1  
BCGD  BCG disease – disseminated  4  4  1  1  1  1  
BCGL*  BCG Lymphadenitis (localised to R 
axilla)  
88  88  1  1  0  0  
BCGP*  BCG Pulmonary  88  88  1  1  0  0  
BCIR*  Recurrent severe presumed bacterial 
infection (excluding pneumonia)   
4  4  0  0  1  1  
BCIS*  Severe presumed bacterial infection – 
single episode (excluding pneumonia)  
88  88  1  1  0  0  
BCNE  Bacterial pneumonia, recurrent (>2 
episodes within 1 year)  
4  3  0  0  1  1  
BCNS*  Severe presumed bacterial pneumonia 
(single episode)  
88  88  1  1  0  0  
BLD*  Unexplained anaemia (<8g/dl), and or 
neutropaenia (<500/mm3 – 2; <1000/mm3 
- children), and or thrombocytopaenia 
(<50000/mm3) > 1 month  
3  3  0  0  1  1  
CANM*  Candidiasis (oral) (outside neonatal 
period)   
3  3  1  1  1  1  
CANO  Candidiasis oesophogeal  4  4  1  1  1  1  
CANT*  Candidiasis (trachea, bronchi or lungs)  4  4  1  1  1  1  
CLD*  Chronic HIV-associated lung disease  88  3  0  1  0  1  
CMO*  HIV-associated cardiomyopathy  88  4  1  1  0  1  
 
CMVO  Cytomegalovirus other location (site other 
than liver, spleen or lymph nodes)  
(onset at age>1month)  
4  4  1  1  1  1  
CMVR  Cytomegalovirus (CMV) chorioretinitis 
(onset at age>1month)  
4  4  1  1  1  1  
CRCO  Cryptococcosis extrapulmonary  4  4  1  1  1  1  
CRSP  Cryptosporidiosis (duration > 1 month)  4  4  0  0  1  1  
CRSPS*  Cryptosporidiosis ?  88  88  1  1  0  0  
CRVC  Cervical cancer (invasive)  4  88  1  1  1  0  
DEM  AIDS dementia complex  4  88  1  0  1  0  
DIAC*  Unexplained chronic diarrhoea (> 1month 
for adults; >14 days for children)  
3  3  0  0  1  1  
DIAS  Diarrhoea (duration <1 month - adults; 
<14 days - children)  
88  88  1  1  0  0  
ENC*  HIV encephalopathy  4  4  1  1  1  1  
FBLS  Focal brain lesion  88  88  1  1  0  0  
FEVC*  Unexplained persistent fever (> 1 month)  3  3  0  0  1  1  
FNID*  Fungal nail infections (fingers or toes)  88  2  0  1  0  1  
FNIF*  Fungal nail infections of fingers  2  88  1  0  1  0  
HERP  Herpes simplex virus ulcers (duration > 1 
month)   
4  4  0  0  1  1  
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HERPS*  Herpes simplex virus ulcers  88  88  1  1  0  0  
HERPV*  Visceral herpes simplex infection  4  4  1  1  1  1  
HG  Hodgkins Lymphoma  88  88  1  1  0  0  
HIST  Histoplasmosis extrapulm.  4  4  1  1  1  1  
HPVE*  Extensive human papilloma virus 
infection   
88  2  1  1  0  1  
HSM*  Hepatosplenomegaly  88  2  0  0  0  1  
HZM*  Herpes zoster (more than one dermatome)  88  88  1  1  0  0  
HZS*  Herpes zoster (single dermatome)   2  2  1  1  1  1  
ISDI  Isosporiasis diarrhoea (duration > 1 
month)  
4  4  0  0  1  1  
ISDS*  Isosporiasis diarrhoea  88  88  1  1  0  0  
KS  Kaposi Sarcoma  4  4  1  1  1  1  
LEIS  Leishmaniasis visceral  4  88  1  1  1  0  
LEU  Progressive multifocal 
leucoencephalopathy  
4  4  1  1  1  1  
LGE*  Lineal gingival erythema  88  2  1  1  0  1  
LIP*  Lymphoid interstitial pneumonitis  88  3  0  1  0  1  
MC  Mycobacterium avium complex (MAC) 
or Kanasii extrapulm.  
4  4  1  1  1  1  
MCDI  Microsporidosis diarrhoea (duration > 1 
month)  
4  4  0  0  1  1  
MCDS*  Microsporidosis diarrhoea  88  88  1  1  0  0  
MCI*  Mycobacterium Immune reconstitution 
syndrome  
88  88  1  1  0  0  
MCP  Mycobacterium tuberculosis pulmonary  3  3  1  1  1  1  
MCPO  Mycobacterium pulmonary other 
(excluding BCG in children)  
88  88  1  1  0  0  
MCX  Mycobacterium tuberculosis 
extrapulmonary  
4  4  1  1  1  1  
MCXO  Mycobacterium extrapulm. other 
(excluding BCG in children)  
4  4  1  1  1  1  
MNUM*  Moderate unexplained malnutrition 
(6080% EWFA)  
88  3  0  1  0  1  
MNUS*  Unexplained severe wasting or 
malnutrition (<60% EWFA)  
88  4  0  1  0  1  
 
MOLC*  Extensive molluscum contagiosum  88  2  1  1  0  1  
MYCD*  Any disseminated mycosis  4  4  1  1  1  1  
NHG  Non-Hodgkin Lymphoma, not specified  88  88  1  1  0  0  
NHGB  Non-Hodgkin Lymphoma, Burkitt  
(classical or atypical)  
88  88  1  1  0  0  
NHGI  Non-Hodgkin Lymphoma, diffuse large 
B-cell lymphoma (immunoblasti or 
centroblastic)  
4  4  1  1  1  1  
NHGP  Non-Hodgkin Lymphoma primary brain 
lymphoma  
4  4  1  1  1  1  
NHGU  Non-Hodgkin Lymphoma unknown/other 
histology  
88  88  1  1  0  0  
NPO*  HIV-associated nephropathy  88  4  1  1  0  1  
NUS*  Acute necrotising ulcerative stomatitis, 
gingivitis or periodontitis  
3  3  1  1  1  1  
OHLP*  Oral hairy leukoplakia  3  3  1  1  1  1  
ORUL*  Recurrent oral ulcerations  2  2  0  0  1  1  
PARE*  Parotid enlargement  88  2  1  1  0  1  
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PCP  Pneumocystis carinii pneumonia   4  4  1  1  1  1  
PGL*  Persistent Generalized Lymphadenopathy  1  1  0  0  1  1  
PPE*  Papular pruritic eruptions  2  2  1  1  1  1  
RTIL*  Lower respiratory tract infection (other 
than presumed pneumonia) ?  
88  88  1  1  0  0  
RTIR*  Recurrent or chronic respiratory tract 
infection (RTIs, sinusitis, bronchitis, otitis 
media, otorrhea, pharyngitis)  
2  2  0  0  1  1  
RTIU*  Upper respiratory tract infection  88  88  1  1  0  0  
RVF*  Acquired HIV-associated recto-vaginal 
fistula  
88  4  1  1  0  1  
SAME  Salmonella bacteraemia (non-typhoid) 
(single episode)  
88  88  1  1  0  0  
SAM  Salmonella bacteraemia (non-typhoid) 
recurrent  
4  88  0  0  1  0  
SEBD*  Seborrheic dermatitis  2  2  1  1  1  1  
TOX  Toxoplasmosis brain (outside neonatal 
period)  
4  4  1  1  1  1  
WAST  HIV Wasting Syndrome  4  88  1  0  1  0  
WTLM*  Moderate unexplained weight loss (<10% 
of body weight)  
2  88  1  0  1  0  
WTLS*  Severe unexplained weight loss (>10% of 
body weight)  
3  88  1  0  1  0  
  
List 4 - Codes for last contact (LAST_CONTACT_T) Code 
source: IeDEA SA codes  
Table name: LU :PAT :LAST_CONTACT_T  
  
Codes  Last contact type  
1  Visit in the facility  
2  Phone call  
3  Home visit  
4  Hospitalisation  
5  Drug pick-up only  
6  Visit in another facility  
7  Laboratory test received  
90  Other  
95   Not ascertained  
99  Unknown despite attempting ascertainment  
  
List 5 - Codes for outcome (OUTCOME)  
Code source: IeDEA SA codes  
Table name: LU :PAT :OUTCOME  
Codes  Mode of infection  
10  Death (HIV-related)  
11  Death (HIV relationship unknown)  
12  Death (not HIV-related)  
20  Alive and in care at your facility  
21  Known to be alive and in care at another facility   
22  Known to be alive and patient is not in care   
23  Known to be alive but not known whether patient is in care  
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30  Transfer out within the same service, vital status after transfer out 
unknown  
31  Transfer out to a different service, vital status after transfer out unknown  
40  Loss to follow-up despite active tracing attempted  
41  Loss to follow-up (not actively traced)  
90  Other  
95  Not ascertained  
List 6 - Codes for cause of death (DEATH_C1 – 3)  
Code source: HICDEP codes; new codes denoted by *  
Table name: LU :PAT :DEATH_C  
  
For HIV-related and Aids defining events (8.*), it is expected that the associated event 
will be recorded in the OI table.  
  
 Codes   Cause of Death   
1   Myocardial Infarction   
2   Stroke   
3   Other cardiovascular diseases   
4   Symptoms caused by mitochondrial toxicity   
4.1   Lactic acidosis   
5   Complications due to diabetes mellitus   
6   Pancreatitis   
7   Complications due to hepatitis   
7.1   Hepatitis related   
7.2   Liver failure not related to hepatitis or mitochondrial toxicity   
8   HIV-related   
8.1   AIDS defining event   
8.2   Invasive bacterial infection   
9   Renal failure   
10   Bleeding (haemophilia)  
20   Non AIDS defining cancer   
88*  Not applicable  
90   Other   
91   Suicide  
92   Drug Overdose   
93  Accident  
95*  Not ascertained  
99  Unknown, Fatal case with no information  
  
List 7 - Codes for primary caregiver (CAREG)   
Code source: IeDEA SA codes  
Table name: LU :PAT :CAREG  
  
Codes  Primary caregiver  
1  Mother  
2  Father  
RCHKIR001  Dissertation for MPH   PART D:  APPENDICES   
Part D: Page 21 of 50   
3  Grandmother  
4  Other family member  
5  Institution  
6  None  
90  Other  
88  Not applicable  
95   Not ascertained  




List 8 - Codes for person informed of the HIV status of the child (DISCL_CG)   
Code source: IeDEA SA codes  
Table name: LU :PAT :DISCL_CG  
  
Codes  Disclosure to caregiver  
1  Mother  
2  Father  
12  Both parents  
3  Grandmother  
4  Other primary caregiver  
90  Other  
88  Not applicable   
95  Not ascertained  
99  Unknown despite attempting ascertainment  
  
2.2  Laboratory data (LAB table)  
Table 2 details the laboratory data that should be included in the LAB table.  All 
available data from the date of first visit should be included.    
  
Notes:  
• Results of laboratory tests must be provided in the units specified  
• Results of laboratory tests can be entered in one of two fields – a numeric field 
(LAB_V) and a coded text field (LAB_T) (for very high and/or undetectable 
viral loads, and for TB microscopy and culture results).  
• TB microscopy and culture results should only be entered in the coded result 
field (LAB_T) as follows, and not in the numeric field (LAB_V):  
• For viral loads, there is an additional field to indicate the lower limit of 
detection of the assay used. This field should be entered as not-applicable (Code 
= -88) for other laboratory results.   
• For TB sensitivity results, there are 2 additional fields. The first (TB_DRUG) 
where the drug to which sensitivity testing has been done is entered, and the 
second (SENS), where the sensitivity is recorded using the standard yes/no 
format. These fields should be entered as not-applicable (Code = 88) for other 
laboratory results.   
• Both CD4 percentage and absolute count should be included on paediatric 
patients until they are 16 years old.  
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• There is no code for unknown values of for laboratory test results as tests of 
which the result is unknown should not be included in the dataset.   
• Only dates in the DMY format are permissible in this table  
  
  
Table 2 – Variables to be included in the table LAB  
Name  Format  Description  
PATIENT  Free (numerical or alphanumerical)  Unique patient identifier  
LAB_DMY  Date (yyyy-mm-dd)  Date when specimen was taken  
LAB_ID  Text (see List 9)  Code representing the measurement  
LAB_V  Numeric (for example 44)  
Numeric value of measurement  
Leave blank if result entered as code (LAB_C)  
LAB_T  
Text   
Lower than limit of detection for 
viral loads should be entered as 
“LDL” TB microscopy and culture 
results should be entered as follows:  





Unknown +  
Text result  
 eg. “> 6 000 000” or “P+++”  




-88 = Not applicable  
-99 = Unknown  
Lower limit of detection of RNA assay  
(Enter -88 for laboratory tests other than viral 
load)  
TB_DRUG  
Text with codes:  
  
INH_L = Isoniazid low dose  
TB Drug against which sensitivity has been 
tested.   
(Enter 88 for laboratory tests other than viral  
 INH_H = Isoniazid high dose INH_U 
= Isoniazid – dose unspecified  
PZA = Pyrazinamide RIF 
= Rifampicin  
ETN = Ethionamide  
ETB = Ethambutol  
STREP = Streptomycin  
QUI = Quinolone  
88 = Not applicable  
load)  
DRUG_RES  
Numeric with codes: 0 
= No (Sensitive)  
1 = Yes (Resistant)  
88 = Not applicable  
  
Is Mycobacterium TB cultured RESISTANT to 
drug in TB-DRUG field?  
(Enter 88 for laboratory tests other than viral 
load)   
  
  
List 9: Codes for measurement type (LAB_ID)  
Code source: HICDEP codes; new codes denoted by *  
Table name: LU :LAB :LAB_ID  
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Codes  Measurement  
ALB  Albumin (g/L)  
ALT  Alanine-Aminotransferase (UI/L)  
AST  Aspartate aminotransferase (UI/L)  
CD4A*  CD4 absolute cell count (cells/μl)  
CD4P*  CD4 percentage (%)  
CHOL  Cholesterol (mmol/L)  
CRE  Creatinine (μmol/L)  
HAEM  Haemoglobin (g/dl)  
LACT  Lactate (mmol/L)  
LYMP  Total lymphocyte count (cells/µl)  
NEUT  Neutrophil count (x1000/mm3)  
PLT  Platelets (cells/μl)  
RNA*  HIV-RNA measurement value (copies/ml)  
TBC*  TB culture  
TBM*  TB microscopy  
TBS*  TB sensitivity  
TG  Triglycerides (mmol/L)  
URE  Urea (mmol/L)  
WBC  White cell count (x1000/ mm3)  
  
2.3 Antiretroviral drug variables (ART table)  
  
Table 3 details the data on antiretroviral treatment that should be included in the ART 
table. As previously mentioned, preferably we will receive one line per drug, each with 
its prescription, start and stop date.    
  
Notes:  
• All antiretroviral drugs to which a patient has been exposed (including PMTCT 
exposure of both pregnant women and infants peri-  or postnatally) and PEP 
should be included with either the dates of starting and stopping the individual 
drugs, OR the number of doses OR the duration of treatment.   
• History of exposure to antiretroviral drugs prior to commencing care at the 
reporting facility should be reconstructed as far as possible and included in this 
table, making use of appropriate drug codes for unknown regimens and 
date/time codes for unknown start and stop dates or unknown durations.   
  
Table 3 – Variables to be included in ART table  
Name  Format  Description  
PATIENT  
Free (numerical or 
alphanumerical)  Unique patient identifier  
ART_ID  ATC (for example NVP – see 
List 10)  Type of antiretroviral drug  
ART_SD_DMY  Date(yyyy-mm-dd)  Date of starting each antiretroviral drug (start 
date).  
Enter exact date in this field if known.  
 If unknown leave blank and enter month and year 
as far as possible in fields below.  
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ART_SD_Y  Numeric (e.g. 2003)  
  
8888 = Exact start date entered 
in appropriate field 9999 = 
Unknown despite attempting 
ascertainment 9995 = Not 
ascertained  
Year of starting drug  
ART_SD_M  Numeric (e.g. 7)  
  
88 = Exact start date entered in 
appropriate field 99 = 
Unknown despite attempting 
ascertainment  
95 = Not ascertained  
Month of starting drug  
ART_RS  Numeric with codes  (See 
List 11)  
Reason for receiving ART   
ART_FORM  Numeric with codes   
  
1 = Tablet/capsule  
2 = Syrup/Suspension  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Type of formulation  
    
 
ART_COMB  Numeric with codes   
  
1 = Individual drug  
2 = Part of a fixed dose  
combination   
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Is drug part of a fixed dose combination?  
ART_ED_DMY  Date(yyyy-mm-dd)  Date of stopping each antiretroviral drug (end 
date)  
Enter exact date in this field if known.  
 If unknown leave blank and enter EITHER month 
and year as far as possible in fields below OR 
number of doses OR duration in weeks in the 
appropriate fields.   
ART_ED_Y  Numeric (e.g. 2004)  
  
8888 = exact end date or 
number of doses or duration in 
weeks entered in appropriate 
fields  
9999 = Unknown despite 
attempting ascertainment 9995 
= Not ascertained  
Year of stopping drug  
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ART_ED_M  Numeric (e.g. 7)  
  
88 = exact end date or number 
of doses or duration in weeks 
entered in appropriate fields  
99 = Unknown despite 
attempting ascertainment  
95 = Not ascertained  
Month of stopping drug  
NO_DOSES  Numeric (e.g. 1)  
  
888 = end date or duration in 
weeks entered in appropriate 
fields  
999 = Unknown despite 
attempting ascertainment 995 
= Not ascertained  
Number of doses of drug e.g. 1 for single dose  
Nevirapine  
NO_WEEKS  Numeric (e.g. 12)  
  
888 = end date or number of 
doses entered in appropriate 
fields  
999 = Unknown despite 
attempting ascertainment 995 
= Not ascertained  
Number of weeks of receiving drug   
e.g. 12 for AZT from 28 weeks of pregnancy  
delivering at term  
ART_END_RS  Numeric with codes  (See 
List 12)  
Reason for stopping antiretroviral drug  
INFO_SOURCE  Numeric with codes   
  
1 = Clinical records at this  
facility  
2 = Clinical records/letter from  
Source of information about ART  
       another facility  
3 = Patient/caregiver report  
4 = Likely protocol in use  
90 = Other  
99 = Unknown  
 
  
List 10: Anti-retroviral drugs :  (ART_ID)  
Code source: ATC classification: Anatomical Therapeutic Chemical  
Table name: LU :ART :ART_ID  
  
ATC codes  Antiretroviral treatment  
J05A   Drug unspecified (i.e. single drug, totally unknown)  
J05AE   PI unspecified   
J05AE01   Saquinavir (gel, not specified)   
J05AE01-SQH   Saquinavir hard gel (INVIRASE)   
J05AE01-SQS   Saquinavir soft gel (FORTOVASE)   
J05AE02   Indinavir (CRIXIVAN)   
J05AE03   Ritonavir (NORVIR)  
J05AE03-H   Ritonavir high dose (NORVIR)   
J05AE03-L   Ritonavir low dose (NORVIR)   
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J05AE04   Nelfinavir(VIRACEPT)  
J05AE05   Amprenavir (141W94) (AGENERASE)   
J05AE06   Lopinavir/Ritonavir (ABT-378/r, Kaletra)   
J05AE07   Fosamprenavir   
J05AE-ATV   Atazanavir (ZRIVADA)  
J05AE-GW4   GW433908/VX-275 (Drug phase III) (PROGENERASE)   
J05AE-TMC   TMC 114 (Tibotec)   
J05AE-TPR   Tipranavir (trial drug)   
J05AF   NRTI unspecified  
J05AF01   Zidovudine (AZT, RETROVIR)   
J05AF02   Didanosine (ddI) (VIDEX)   
J05AF03   Zalcitabine (ddC) (HIVID)   
J05AF04   Stavudine (d4T) (ZERIT)   
J05AF05   Lamivudine (3TC, EPIVIR)   
J05AF06   Abacavir (1592U89) (ZIAGEN)   
J05AF07   Tenofovir (TDF, VIREAD)   
J05AF08   Adefovir (PREVEON)   
J05AF09   Emtricitabine (FTC, EMTRIVA)   
J05AF10   Entecavir   
J05AF30-KIV   Kivexa   
J05AF30-TZV   Trizivir   
J05AF-FOZ   Fozivudinetidoxi  
J05AF-LDN   Lodenosine (trialdrug)   
J05AG   NNRTIunspecified   
J05AG01   Nevirapine (VIRAMUNE)   
J05AG01-SD   Nevirapine (VIRAMUNE) single dose  
J05AG02   Delavirdine (U-90152) (RESCRIPTOR)   
J05AG03   Efavirenz (DMP-266) (STOCRIN, SUSTIVA)   
J05AG-LOV   Loviride   
J05AG-TMC   TMC 125 (Tibotec)   
J05A-PBT   Participant in Blinded Trial   
J05AR*   ART regimen and drug unspecified (i.e. both number and names 
of drugs totally unknown)  
J05AX07   Enfurvirtide (FUZEON, T-20/Ro 29-9800)   
L01XX05   Hydroxyurea/Hydroxycarbamid (LITALIR)   
  
List 11: Codes for reason for receiving ART (ART_RS)  Code 
source: IeDEA SA codes   
Table name: LU :ART :ART_RS  
  
Codes  Reason  
10  MTCT – antenatal (mother)  
11  MTCT – peripartum (mother)  
12  MTCT – postpartum (mother)  
13  MTCT – timing unknown (mother)  
20  MTCT – peripartum (infant)  
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21  MTCT – postpartum (infant)  
22  MTCT – timing unknown (infant)  
30  ARV as treatment  
40   PEP  
95  Not ascertained  
99  Unknown despite attempting ascertainment  
  
List 12: Reason for treatment discontinuation (ART_END_RS)   
Code source: HICDEP codes; new codes denoted by *  
Table name: LU :ART :ART_END_RS  
Codes  Reason for treatment discontinuation  AE  CI  FL  Other  
1  Treatment failure (i.e. virological, immunological,      1    
1.1  Virological failure              1    
1.2  Partial virological failure      1    
1.3  Immunological failure – CD4 drop      1    
1.4  Clinical progression      1    
10  Hyperlactataemie/lactic acidosis  1        
2  Abnormal fat redistribution  1        
3  Concern of cardiovascular disease  1        
3.1  Dyslipidaemia  1        
3.2  Cardiovascular disease  1        
4  Hypersensitivity reaction  1        
5  Toxicity, predominantly from abdomen/G-I tract  1        
5.1  Toxicity – GI tract  1        
5.2  Toxicity – Liver  1        
5.3  Toxicity – Pancreas  1        
6  Toxicity, predominantly from nervous system  1        
6.1  peripheral neuropathy  1        
7  Toxicity, predominantly from kidneys  1        
8  Toxicity, predominantly from endocrine system  1        
8.1  Diabetes  1        
88  Death (note overlap with N/A in other lists)        1  
9  Haematological toxicity (anemia …etc.)  1        
90  Side effects – any of the above but unspecified  1        
90.1  Comorbidity    1      
91  Toxicity, not mentioned above  1        
92  Availability of more effective treatment (not 
specifically failure or side effect related)  
      1  
92.1  Simplified treatment available        1  
92.2  Treatment too complex        1  
92.3  Drug interaction    1      
92.4  Drug interaction - commencing TB treatment    1      
92.5  Drug interaction ended - stopping TB treatment        1  
93  Structured Treatment Interruption (STI)        1  
93.1  Structured Treatment Interruption (STI) – at high        1  
94  Patient's wish/ decision, not specified above          1  
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94.1  Non-compliance        1  
95  Physician’s decision, not specified above (note 
overlap with standard code  
      1  
95.1*  Contra-indication expired        1  
96  Pregnancy    1      
96.1*  MTCT regimen completed        1  
96.2*  Pregnancy ended        1  
97  Study treatment        1  
98  Other causes, not specified above        1  
99  Unknown despite attempting ascertainment        1  
99.5  Not ascertained        1  
2.4 Opportunistic events (OI table)  
Table 4 below details the data on opportunistic events or HIV associated conditions 
diagnosed during follow up that should be included in table OI.  
  
History of opportunistic events prior to commencing care at the reporting facility 
should be reconstructed as far as possible and included in this table, making use of 
appropriate date/time codes for unknown start and end dates. It is anticipated that the 
end date of OIs will frequently be unknown.   
  
Table 4 – Variables to be included in OI table  
Name  Format  Description  
PATIENT  Free (numerical or alphanumerical)  Unique patient identifier  
OI_ID  
Text (for example PCP - see List 3 – 
Disease codes – under PAT table)   
Type of opportunistic event  
OI_SD_DMY  Date(yyyy-mm-dd)  
Date of start of each opportunistic event.  
Enter exact date in this field if known.  
If unknown leave blank and enter month  
and year as far as possible in fields below.  
OI_SD_Y  
Numeric (e.g. 2001)  
  
8888 = Not applicable  
(Exact date entered in field above)  
9995 = Not ascertained  
9999 = Unknown despite attempting 
ascertainment  
Year of start of event  
OI_SD_M  
Numeric (e.g. 11)  
  
88 = Not applicable   
Month of start of event  
 (Exact date entered in field above)  
95 = Not ascertained  
99 = Unknown despite attempting 
ascertainment  
 
OI_ED_DMY  Date(yyyy-mm-dd)  
Date of end of each opportunistic event.  
Enter exact date in this field if known.  
 If unknown leave blank and enter month 
and year as far as possible in fields below 
If OI is ongoing (has not yet ended) leave 
blank and enter appropriate code in field  
below  
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OI_ED_Y  
Numeric (e.g. 2001)  
  
8885 = Ongoing  
8888 = Not applicable  
(Exact date entered in field above)  
9995 = Not ascertained  
9999 = Unknown despite attempting 
ascertainment  
Year of end of event  
OI_ED_M  
Numeric (e.g. 11)  
  
85 = Ongoing  
88 = Not applicable   
(Exact date entered in field above) 95 
= Not ascertained  
99 = Unknown despite attempting 
ascertainment  
Month of end of event  
DIAG_METH  
Numeric (see List 13 )  Method of diagnosis  
  
List 13: Diagnosis Method of Opportunistic Event (DIAG_METH)   
Code source: IeDEA SA codes  
Table name: LU :OI :DIAG_METH  
  
Codes  Diagnosis Method  
10  clinical only  
11  clinical & radiology  
12  clinical and endoscopy  
20  microscopy for infectious agent  
21  culture of infectious agent  
30  blood antibody test  
31  site specimen (non-blood) antibody test  
40  tissue histology  
90  other  
95  Not ascertained  
99  Unknown despite attempting ascertainment  
  
2.5 Follow-up clinic visits (VIS table)  
Table 5 below details the clinical visit information. Please include all visits for each 
patient since the first visit at the reporting facility, and where possible visits at previous 
facilities. Weight, height and head circumference left blank will be assumed to have not 
been ascertained.  
  
Table 5 – Variables to be included in VIS table   
Name  Format and definitions  Description  
PATIENT  Free (numerical or alphanumerical)  Unique patient identifier  
VISIT_DMY  Date (yyyy-mm-dd)  Date of visit patient  
VISIT_FAC  
Numeric with codes  
1 = Visit at this cohort’s facility  
2 = Visit at another facility  
99 = Site of visit unknown  
Facility at which visit took place  
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WEIGHT  Numeric (for example 75)  Weight in kilos (kg)  
HEIGHT  Numeric (for example 75)  Height in centimeters (cm)  
TB_STATUS  
Numeric with codes  
0 – No symptoms  
2– Symptoms with sputum  
3 – Symptoms no sputum  
4 – On TB treatment  
95– Not screened  
99– Screening status unknown  
Patient’s TB status on date of clinical 
visit.  
WHO_STAGE  
Numeric with codes:  
1 = Stage I  
2 = Stage II  
3 = Stage III  
4 = Stage IV  
95 = Not ascertained  




Numeric with codes :  
1 = yes  
0 = No  
95 = Not ascertained  
99 = Unknown despite attempting 
ascertainment   
Cotrimoxazole status  
INH  
Numeric with codes :  
1 = Yes  
0 = No  
95 = Not ascertained  
99 = Unknown despite attempting 
ascertainment  
Isoniazid status  
FLU  
Numeric with codes :  
1 = Yes  
0 = No  
95 = Not ascertained  
99 = Unknown despite attempting 
ascertainment  
Fluconazole status  
HEADC  Numeric (for example 75)  
Head circumference in centimeters  
(cm)  
SCHOOL_Y  Numeric with codes  Schooling for children >5 years.   
 0 = No school  
1 = At school  
88 = Not applicable  
95 = Not ascertained  
For adults and children less than 5 
years,  enter 88.  
2.6 Demographic Information ( DEM table)  
  
Table 6 below details the data that should be included in DEM table.   
  
Table 6 – Variables to be included in DEM table  
Name  Format and definitions  Description  
PATIENT  
Free (numerical or alphanumerical)  
Unique, anonymous, patient identifier  
FOLDER_NUMBER  Text  
Text field identifying the unique patient 
folder number.  
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OTHER_NUMBER  Text  
Text field identifying any other unique 
patient identifier e.g. Passport number.  
SURNAME  Text  Patient’s last name.  
FIRST_NAME  Text  Patient’s first name.  
BIRTH_DATE  Date (yyyy-mm-dd)  
Date of birth   
Enter exact date in this field if known.  
  
DEATH_DATE  Date (yyyy-mm-dd)  
Date of death    
Enter exact date in this field if known.  
  
GENDER  
Text.   
The following options exist:  
  
1 = Male  
2 = Female  
95 = Indeterminate  
Sex / gender of patient  
RACE  
Text.   
The following options exist:  
  
- Asian  
- Black  
- Coloured  
- White  
- Other  
  
Race of patient.  
HOME_ADDRESS_1  Text  Address details for the patient   
HOME_ADDRESS_2  Text  Address details for the patient  
HOME_ADDRESS_3  Text  Address details for the patient  
HOME_ADDRESS_4  Text  Address details for the patient  
POST_CODE  Text  
Postal code for area or suburb that the 
patient resides.  
CELL_NUMBER  Text  Cell phone number of patient.  
MARITAL_STATUS  
Text  
(e.g. Divorced, Married)  
  
Marital status of patient.  
HOME_LANGUAGE  
Text  




Language used by patient at home.  
3 Variables to be included in additional tables  
3.1 Family and partner linkages (LINK table)  
  
Table 6 details the information on family members (partners, children and siblings) that 
should be included in the LINK table.  
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All family members receiving HIV care should be listed. This includes those receiving 
care within the reporting cohort as well as those receiving care at other sites.  
  
The cohort-specific identifiers of family members receiving HIV care at the reporting 
site should be included.   
  
Table 6 – Variables to be included in the table LINK  
Name  Format  Description  
PATIENT  Free (numerical or alphanumerical)  Unique patient identifier  
LINK_REL  Numeric with codes (See List 14)  Relationship of family member to patient  
LINK_COHORT  Text with codes (See List 15)  
Cohort within which family member is 
receiving HIV care  
LINK_ID  
Free (numerical or alphanumerical)  
-88 = Not applicable  
-95 = Not ascertained  
-99 = Unknown despite attempting 
ascertainment  
Unique patient identifier of family member  
Enter -88 if family member in care at 
nonIeDEA site.  
  
List 14 - Codes for relationship of family member to patient (LINK_REL)  Code 
source: IeDEA SA codes  
Table name: LU :LINK :LINK_REL  
  
Codes  Relationship  
1  Mother  
2  Father  
3  Child  
4  Sibling  
5  Spouse/partner  
90  Other  
95   Not ascertained  
99  Unknown despite attempting ascertainment  
  
List 15 - Cohort where family member is receiving care (LINK_COHORT)   
Code source: To be created by transferring site  
Table name: LU :LINK :LINK_COHORT  
  
Codes  Cohort  
Cohort ID  Cohort description  
3.2 Pregnancy information (PREGNANCY table)   
  
Table 7 details information to be included in the PREGNANCY table. This table 
contains information on all pregnancies since the patient was known to be HIVinfected, 
including spontaneous abortions/ miscarriages and terminated pregnancies, and their 
outcomes.   
  
Table 7 – Variables to be included in PREGNANCY table  
Name  Format  Description  
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PATIENT  
Free (numerical or 
alphanumerical)  Unique patient identifier for patient  
PREG_DIAG_DMY  
Date (yyyy-mm-dd)  
Exact date when patient first presents as 
pregnant  
PREG_DUR_DIAG  Numeric (e.g. 12) 99 
= Unknown  
Estimated duration of pregnancy in weeks 
when patient first presents as pregnant  
PREG_END_DMY  Date (yyyy-mm-dd)  Exact date of delivery, spontaneous abortion 
or termination  
Enter exact date in this field if known.  
 If unknown leave blank and enter month and 
year as far as possible in fields below.  
PREG_END_Y  Numeric (e.g. 2003)  
  
8888 = Not applicable (Exact 
date entered in field above)  
9995 = Not ascertained  
9999 = Unknown despite 
attempting ascertainment  
Year of delivery, spontaneous abortion or 
termination  
PREG_END_M  Numeric (e.g. 9)  
  
88 = Not applicable  
(Exact date entered in field 
above)  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Month of delivery, spontaneous abortion or 
termination  
PREG_ED  Numeric (e.g. 36)  
  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Estimated duration of entire pregnancy in 
weeks  
PREG_OUTCOME  Numeric with codes   
  
1 = Live birth  
2 = Still birth  
3 = Termination of  
pregnancy  
4= Spontaneous abortion   
     (miscarriage)  
95 = Not ascertained  
99 = Unknown despite 
attempting          
ascertainment  
Outcome of pregnancy  
INF_WT  Numeric (e.g. 2.9)  
  
88 = Not applicable  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Weight of delivered infant.  
If spontaneous abortion or termination, enter 
88  
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NEONATAL_DEATH  Numeric with codes  
  
0 = No  
1 = Yes   
88 = Not applicable  
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Did delivered live infant die within 1 month 
of birth?  
If stillbirth, spontaneous abortion or 
termination, enter 88  
BIRTH DEFECT_Y  Numeric with codes  
  
0 = No  
1 = Yes   
95 = Not ascertained  
99 = Unknown despite 
attempting ascertainment  
Did fœtus or infant have any congenital 
malformations?  
BIRTH_DEFECT_TYPE  Text  Free text description of malformations  
  
3.3 Parental Health (PAR_HEALTH table)   
  
Table 8 details variables to be included in the table PAR_HEALTH. This table contains 
information on parental health status.   
  
This table is linked to the visit table, so ideally there is an update on parental health 
status at every visit. Alternatively, this table should be filled in at least once, either for 
the first visit at your facility or the date of start of HAART.   
  
For patients over 16 years of age, no entries are required into this table (i.e. this table is 
not required at all for sites that have only patients over 16 years of age in their care).   
  
While information on parental health is very valuable, it is acknowledged that many 
sites do not collect this information. If only information at the child’s first visit or at the 
start of HAART is collected, this should be included with the appropriate visit date.  
If no information on parental health is collected, this table can be omitted.    
Table 8: Variables to be included in the PAR_HEALTH table  
Name  Format  Description  
PATIENT  Free (numerical or alphanumerical)  
Unique patient identifier for 
patient  
VIS_DMY  
Date (dd/mm/yy)  
Date of parental health 
evaluation   
(probably same as clinic visit 
date)  
MAT_DEATH  Numeric with codes  
  
0 = No (Alive)  
1 = Yes (Dead)  
95 = Not ascertained  
99 = Unknown despite attempting ascertainment  
Maternal status: Mother 
deceased?  
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MAT_HIV  Numeric with codes  
  
0 = Negative  
1 = Positive  
95 = Not ascertained  
99 = Unknown despite attempting ascertainment  
Mother’s HIV status if 
available  
MAT_TTT  Numeric with codes  
  
0 = No treatment  
1 = CMX only  
2 = HAART only  
12 = CMX and HAART  
88 = Not applicable (mother HIV negative or 
deceased)  
95 = Not ascertained  
99 = Unknown despite attempting ascertainment  
Mother’s treatment if available  
PAT_DEATH  Numeric with codes  
  
0 = No (Alive)  
1 = Yes (Dead)  
95 = Not ascertained  
99 = Unknown despite attempting ascertainment  
Paternal status: Father 
deceased?  
PAT_HIV  Numeric with codes  
  
0 = Negative  
1 = Positive  
95 = Not ascertained  
99 = Unknown despite attempting ascertainment  
Father’s HIV status if available  
PAT_TTT  Numeric with codes  
  
0 = No treatment  
1 = CMX only  
2 = HAART only  
12 = CMX and HAART  
88 = Not applicable (father HIV negative or 
deceased)  
95 = Not ascertained  
99 = Unknown despite attempting ascertainment  
Father’s treatment if available  
3.4 Tuberculosis information (TB table)  
This table is for capturing details of the TB episodes during HIV follow-up.  Tests 
related to TB can be included in the LAB table.  Where possible this data can be 
derived from the electronic TB register.  
  
Table 9 – Variables to be included in the table TB  
Name  Format  Description  
PATIENT  Free (numerical or alphanumerical)  Unique patient identifier  
REG_DMY  Date (dd/mm/yy)  Date registered with TB  
REGID  
Text (eg. 2272007)  
-95 = Not ascertained  
-99 = Unknown despite attempting 
ascertainment  
TB register number  
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RAD  
 
Numeric with codes  
  
0 – Not done  
1 – Normal  
20 – Abnormal unspecified  
21 – Abnormal - not consistent with 
current  
TB  
22 – Abnormal - consistent with 
current TB unspecified  
23 – Abnormal – consistent with 
current TB  
–   
Cavity on right  
24 - Abnormal – consistent with 
current TB  
–   
Cavity on left  
25 - Abnormal – consistent with 
current TB  
–  
Bilateral cavities  
26 - Abnormal – consistent with 
current TB  
-   
No cavities  
99 = Unknown despite attempting 
ascertainment  
Radiography findings if done  
RESISTANT  
Numeric with codes  
  
0 – No  
1 – MDR  
2 – XDR  
95 = Not ascertained  
99 = Unknown despite attempting 
ascertainment  
Resistance data based on sensitivities  
Note: Exact results of sensitivities should be record in 
the LAB table.  Code as MDR if … to more than one 
drug and XDR if…  
Categories MDR and XDR should be for the worst 
resistance status during the episode.   
   
TB_START_DMY  Date (dd/mm/yy)  Date starting TB treatment  
TB_END_DMY  Date (dd/mm/yy)  Date ending TB treatment or date of outcome  
CAT  
Numeric with codes  
  
1 – Newly diagnosed for the first time  
2 – After relapse  
3 – After default  
4 – After failure  
95 = Not ascertained  
99 = Unknown despite attempting 
ascertainment  
TB Category  
CLASS  
Numeric with codes  
  
1 - Pulmonary  
2 – Extra-pulmonary  
Classification of episode  
 3 – Both pulmonary and extra-pulmonary  
4 - Primary  
95 = Not ascertained  
99 = Unknown despite attempting 
ascertainment  
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SITE  
Numeric with codes  
  
1 – Bones/Joints (A18.0)  
2 – Lymph nodes (A16.3)  
3 – Meningitis (A17.0)  
4 – Miliary (A19.9)  
5 – Pleura (A16.5)  
9 – Other sites (A18.8)  
88 – Not applicable as pulmonary or primary 
only  
95 = Not ascertained  
99 = Unknown despite attempting 
ascertainment  
Site of disease if extra-pulmonary component 
diagnosed  
REGIMEN  
Numeric with codes  
  
1 – 2HRZE 4HR - Regimen 1  
2 –2HRZES 1HRZE 5HRE - Regimen 2  
3 – 2HRZ 4HR - Regimen 3  
4 –Other Regimen  
95 = Not ascertained  
99 = Unknown despite attempting 
ascertainment  
TB treatment regimen   
REG_OTHER  Text  
Text field for other regimen not included in 
codes for REGIMEN field above  
TB_OUTCOME  
Numeric with codes  
  
1 – Completed  
2 – Cured  
3 – Failed  
4 – Interrupted  
5 – Defaulted  
6 – Treatment ongoing  
7 - Died  
95 = Not ascertained  
99 = Unknown despite attempting 
ascertainment  
Outcome of TB episode  
  
3.5 Trial/research study enrolment information (TRIAL table)  
  
Table 10 details the data that should be included in the TRIAL table.  This table is only 
for sites running trials or research studies. Any trial/research study (apart from cohort 
analysis of routine data) on which a patient has been enrolled should be entered 
together with the dates of entering and leaving each trial. Sites should send an 











Table 11 – Variables to be included in the table TRIAL  
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Name  Format  Description  
PATIENT  
Free (numerical or 
alphanumerical)  Unique patient identifier  
TRIAL_START_DMY  Date (yyyy-mm-dd)  Date of enrolment onto trial  
TRIAL_END_DMY  Date (yyyy-mm-dd)  
Date of completion/ disenrolment   
Leave blank if patient is still enrolled on 
trial  
TRIAL_ID  
Free (numeric or text) codes (See 
List 16)  
Name of trial on which patient is enrolled 
Each site to send their own List with 
coding and description of trial  
  
List 16: Example of codes for trial name (TRIAL_ID)   
Code source: Site to supply own codes  
Table name: LU :TRIAL :TRIAL_ID  
  
Codes   
(Text or  
Numeric)  
Trial name (text field)  Short description of trial (Memo field)  
INH  INH trial  Trial of thrice weekly vs daily INH 
prophylaxis in HIV-infected children  
TB  TB treatment duration  
trial  
Trial of 6 month vs 9 month  
chemotherapy in HIV-infected children  
  
  
4 Meta-data  
  
This table contains information about the data transfer itself.  
  
Table 12 – Variables to be included in the table META  
Name  Format  Description  
COHORT  Text  Name of the cohort   
ENROLS_DMY  Date (yyyy-mm-dd)  Date of start of enrolment  
ENROLE_DMY  Date (yyyy-mm-dd)  Date of end of enrolment  
FU_CLOSE_DMY  Date (yyyy-mm-dd)  Date of last possible follow-up  
ASC_DMY  Date (yyyy-mm-dd)  Date of last possible outcome ascertainment  
LTF_DEF  Numeric  
For patients classified by the site as LTF, the 
number of days used to define LTF  
REPORTER  Text  Name of person responsible for data transfer  
TRANSFER_DMY  Date (yyyy-mm-dd)  Date extracted  
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Appendix 2:  The Pediatric Infectious Disease Journal (PIDJ) Online Submission and  
  Review System  
  
SCOPE  
The Pediatric Infectious Disease Journal is a peer-reviewed, multidisciplinary journal directed 
to physicians and other health care professionals who manage infectious diseases of 
childhood.  
  
Ethical/Legal Considerations   
A submitted manuscript must be an original contribution not previously published (except as 
an abstract or preliminary report), must not be under consideration for publication 
elsewhere, and, if accepted, must not be published elsewhere in similar form, in any 
language, without the consent of Lippincott Williams & Wilkins. Each person listed as an 
author is expected to have participated in the study to a significant extent. Although the 
editors and referees make every effort to ensure the validity of published manuscripts, the 
final responsibility rests with the authors, not with the journal, its editors, or the publisher. All 
manuscripts must be submitted on-line through the journal's web site at 
http://pidj.edmgr.com/. See submission instructions under "Online manuscript submission."   
  
Patient anonymity and informed consent: It is the author's responsibility to ensure that a 
patient's anonymity be carefully protected and to verify that any experimental investigation 
with human subjects reported in the manuscript was performed with informed consent and 
following all the guidelines for experimental investigation with human subjects required by 
the institution(s) with which all the authors are affiliated. Authors should mask patients' eyes 
or, if the eye area is the focus of the illustration, the patient's nose and mouth, and they 
should remove patients' names from figures unless written consent obtained from the 
patients is submitted with the manuscript.   
  
Copyright: All authors must sign a copy of the journal's "Authorship Responsibility, Financial  
Disclosures, and Copyright Transfer" form and submit it at the time of manuscript submission.   
  
Conflicts of interest: Authors must state all possible conflicts of interest in the manuscript, 
including financial, consultant, institutional and other relationships that might lead to bias or 
a conflict of interest. If there is no conflict of interest, this should also be explicitly stated as 
none declared. All sources of funding should be acknowledged in the manuscript. All relevant 
conflicts of interest and sources of funding should be included on the title page of the 
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manuscript with the heading “Conflicts of Interest and Source of Funding:”. For example:  
Conflicts of Interest and Source of Funding: A has received honoraria from Company Z. B is 
currently receiving a grant (#12345) from Organization Y, and is on the speaker’s bureau for 
Organization X – the CME organizers for Company A. For the remaining authors none were 
declared.   
In addition, each author must complete and submit the journal’s copyright transfer 
agreement, which includes a section on the disclosure of potential conflicts of interest based 
on the recommendations of the International Committee of Medical Journal Editors,  
“Uniform Requirements for Manuscripts Submitted to Biomedical Journals”  
(www.icmje.org/update.html). The form is readily available on the manuscript submission 
page www.editorialmanager.com/pidj/ can be completed and submitted electronically. 
Please note that authors may sign the copyright transfer agreement form electronically. For 
additional information about electronically signing this form, go to 
http://links.lww.com/ZUAT/A106.   
Compliance with NIH and Other Research Funding Agency Accessibility Requirements A 
number of research funding agencies now require or request authors to submit the postprint 
(the article after peer review and acceptance but not the final published article) to a 
repository that is accessible online by all without charge. As a service to our authors, LWW 
will identify to the National Library of Medicine (NLM) articles that require deposit and will 
transmit the post-print of an article based on research funded in whole or in part by the 
National Institutes of Health, Wellcome Trust, Howard Hughes Medical Institute, or other 
funding agencies to PubMed Central. The revised Copyright Transfer Agreement provides the 
mechanism.  
  
Permissions: Authors must submit written permission from the copyright owner (usually the 
publisher) to use direct quotations, tables, or illustrations that have appeared in copyrighted 
form elsewhere, along with complete details about the source. Any permissions fees that 
might be required by the copyright owner are the responsibility of the authors requesting use 
of the borrowed material, not the responsibility of Lippincott Williams & Wilkins.   
  
Preparation of Manuscript   
Manuscripts that do not adhere to the following instructions are returned to the 
corresponding author for technical revision before undergoing peer review. Also, to 
streamline the review process, on reviewing newly submitted manuscripts, we will identify 
those that do not meet the mission of the journal, provide no new information or insights 
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into management of infectious diseases or are of more local importance and better suited for 
a regional journal and return them immediately to the authors to allow them to submit their 
work elsewhere in a timely fashion.   
  
New Article Types   
  
Research Reports This section comprises manuscripts on all aspects of the molecular 
pathogenesis and immunologic mechanisms of bacterial, viral, fungal and other infections in 
infants, children and adolescents. The emphasis will be on manuscripts that present data that 
are clinically applicable and provide a more thorough understanding of the pathophysiologic 
basis of infections in children and that could impact eventual treatment and prevention. The 
manuscripts can be formatted as original studies or brief reports and will be peer reviewed.   
  
HIV Reports The section comprises of high-quality, high-impact original articles and brief 
reports of epidemiologic, clinical, translational and implementation science studies pertaining 
to the prevention, treatment and outcomes of HIV infection in infants, children, 
andadolescents.  
  
Vaccine Reports Articles that present data from Vaccine Phase II-IV studies will appear in this 
section. These manuscripts receive the same peer review as articles submitted as Original 
Studies. The universal open access fee for all accepted manuscripts in this category is: 
$1500.00 US, plus an additional per-page fee with 2 options: 1) $50 per page for print and 
online publication; or 2) $25 per page for online only publication. All articles in this series will 
be available online by free access. For manuscripts in this category, authors should refer to 
the “Guidelines for collection, analysis and presentation of vaccine safety data in pre- and 
post-licensure clinical studies” published in Vaccine (2009, vol. 27; pp 2282-8) and use case 
definitions as developed by The Brighton Collaboration (www.brightoncollaboration.org) 
whenever possible.  
  
Manuscript Submission   
  
Online manuscript submission: All manuscripts must be submitted on-line through the new 
web site at http://pidj.edmgr.com/. First-time users: Please click the Register button from the 
menu above and enter the requested information. On successful registration, you will be sent 
an E-mail indicating your user name and password. Print a copy of this information for future 
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reference. Note: If you have received an E-mail from us with an assigned user ID and 
password, or if you are a repeat user, do not register again. Just log in. Once you have an 
assigned ID and password, you do not have to re-register, even if your status changes (that is, 
author, reviewer, or editor). If you experience any problems, please contact Amy Newman, 
Journal Manager, at PIDJournal@yahoo.com, Ph 830-865-1249, Fax 214-710-2175.   
  
Authors: Please click the log-in- button from the menu at the top of the page and on the next 
screen log into the system as an Author. Submit your manuscript according to the author 
instructions. You will be able to track the progress of your manuscript through the system. If 
you experience any problems, please contact Amy Newman, Journal Manager, at 
PIDJournal@yahoo.com, Ph 830-865-1249, Fax 214-710-2175. Requests for help and other 
questions will be addressed in the order received. To submit a completed manuscript, the 
following documents are required: Cover Letter, Title Page, Abstract, and Manuscript. Tables 
and figures are optional. Each portion of the manuscript must be submitted as separate 
documents (i.e. cover letter, title page, abstract, manuscript, tables and figures all saved as 
separate files). The text documents, cover letter, title page, abstract and manuscript are to be 
uploaded as Microsoft Word documents. Tables are to be created in Microsoft Word also.  
Excel tables will not load properly. All figures should be TIFF, EPS or PowerPoint files.   
  
General format: Submit manuscripts in English. Double space all copy, including legends, 
footnotes, tables, and references. Use a common font such as Arial or Times Roman in size 
12. Enumerate all pages of the manuscript, beginning with the Title Page as page 1, and 
follow in sequence to the abstract, manuscript and all other attachments. If you are 
unfamiliar with numbering, you can search HELP while in Microsoft Word, and it will show in 
detail how to number all pages.  
   
Title page: Title page must be submitted as a separate file. Include on the title page: (a) 
complete manuscript title; (b) authors' full names, highest academic degrees, and affiliations; 
(c) name and address for correspondence, including Fax number, telephone number, and 
Email address; (d) address for reprints if different from that of corresponding author (indicate 
whether reprints are available); and (e) all sources of support, including pharmaceutical and 
industry support, that require acknowledgment; (f) list three to five key words for indexing; (g) 
an abbreviated title of 55 characters or less used for the cover of the journal; (h) a running 
head title of 44 characters or less including spaces used for page headings on the pages in 
which your article is published.   
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The title page must also include disclosure of funding received for this work from any of the 
following organizations: National Institutes of Health (NIH); Wellcome Trust; Howard Hughes 
Medical Institute (HHMI); and other(s).   
  
Structured abstract for Original Studies and Supplement Articles: Abstracts must be 
submitted as a separate file. Limit the abstract to 250 words. Do not cite references in the 
abstract. Limit the use of abbreviations and acronyms. Use the following subheads:   
Background, Methods, Results, and Conclusions (others may be added as needed).   
  
Unstructured abstract for Instructive Cases and Brief Reports: Abstract must be submitted as 
a separate file. Limit the abstract to 60 words. It must be factual and comprehensive. Limit 
the use of abbreviations and acronyms, and avoid general statements (e.g. "the significance 
of the results is discussed").   
  
Text: Organize the manuscript into four main headings, Introduction, Materials and Methods, 
Results, and Discussion. If a brand name is cited, supply the manufacturer's name and 
address (city and state/country).   
  
Abbreviations: For a list of standard abbreviations, consult the American Medical Association 
Manual of Style, 9th edition, or other standard sources. Write out the full term for each 
abbreviation at its first use unless it is a standard unit of measure. Abbreviations are allowed 
only if used three times or more in text.   
  
References: The authors are responsible for the accuracy of the references. Key the 
references (double-spaced) at the end of the manuscript. Cite the references in text in the 
order of appearance, including those references cited in tables and figure legends at the 
chronological citation of the tables and figures in text. Cite unpublished data, such as papers 
submitted but not yet accepted for publication or personal communications, in parentheses 
in the text. If there are more than six authors, name only the first three authors and then use 
et al. Refer to the List of Journals Indexed in Index Medicus for abbreviations of journal 
names, or access the list at http://www.nlm.nih.gov/tsd/ serials/lji.html. Sample references 
are given below.   
  
Journal article  
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1. Trujillo M, Correa N, Olsen K, et al. Cefprozil concentrations in middle ear fluid. Pediatr Infect 
Dis J. 2000;19:268 –270.   
  
Book chapter   
2. Grose C. Bacterial myositis and pyomyositis. In: Feigin RD, Cherry JD, eds. Textbook of 
Pediatric Infectious Diseases. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 1998:704 – 
708.   
  
Entire book   
3. Nelson JD, Bradley JS. Nelson's Pocket Book of Pediatric Antimicrobial Therapy. 14th ed.  
Philadelphia: Lippincott Williams & Wilkins; 2000.   
  
Proceedings   
4. Harrigan PR, Dong W, Weber AE, et al. Highly mutated RT and protease [Abstract I-115]. In:  
38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 
September 24 to 27, 1998. Washington, DC: American Society for Microbiology; 1998.   
  
Online journals   
5. Friedman SA. Preeclampsia. Obstet Gynecol. [serial online]. January 1988;71:22–37.  
Available from: BRS Information Technologies, McLean, VA. Accessed December 15, 1990.   
World Wide Web   
6. Gostin LO. Drug use and HIV/AIDS [JAMA HIV/AIDS web site]. June 1, 1996. Available at:  
http://www.ama-assn.org/ special/hiv/ethics. Accessed June 26, 1997.   
  
Figures:   
A) Creating Digital Artwork   
Learn about the publication requirements for Digital Artwork: http://links.lww.com/ES/A42   
Create, Scan and Save your artwork and compare your final figure to the Digital Artwork 
Guideline Checklist (below).   
Upload each figure to Editorial Manager in conjunction with your manuscript text and tables.   
B) Digital Artwork Guideline Checklist  
Here are the basics to have in place before submitting your digital artwork:   
Artwork should be saved as TIFF, EPS, or MS Office (DOC, PPT, XLS) files. High resolution PDF 
files are also acceptable.   
Crop out any white or black space surrounding the image.   
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Diagrams, drawings, graphs, and other line art must be vector or saved at a resolution of at 
least 1200 dpi. If created in an MS Office program, send the native (DOC, PPT, XLS) file.  
Photographs, radiographs and other halftone images must be saved at a resolution of at least 
300 dpi.   
Photographs and radiographs with text must be saved as postscript or at a resolution of at least 
600 dpi.   
Each figure must be saved and submitted as a separate file. Figures should not be embedded in 
the manuscript text file.   
  
Remember:   
Cite figures consecutively in your manuscript.   
Number figures in the figure legend in the order in which they are discussed.   
Upload figures consecutively to the Editorial Manager web site and enter figure numbers 
consecutively in the Description field when uploading the files.   
Figure legends: Include legends for all figures. They should be brief and specific, and they 
should appear on a separate manuscript page after the references. Legends should be part of 
the manuscript file on the disk. Use scale markers in the image for electron micrographs, and 
indicate the type of stain used.   
Color figures: The journal accepts for publication color figures that enhance an article. 
Authors who submit color figures receive an estimate of the cost for color reproduction. If 
they decide not to pay for color reproduction, they can request that the figures be converted 
to black and white at no charge.   
  
Supplemental Digital Content   
Supplemental Digital Content (SDC): Authors may submit SDC via Editorial Manager to LWW 
journals that enhance their article's text to be considered for online posting. SDC may include 
standard media such as text documents, graphs, audio, video, etc. On the Attach Files page of 
the submission process, please select Supplemental Audio, Video, or Data for your uploaded 
file as the Submission Item. All SDC files should be uploaded as the author would like them 
presented in the final article. If an article with SDC is accepted, our production staff will 
create a URL with the SDC file. The URL will be placed in the call-out within the article. SDC 
files are not copyedited by LWW staff, they will be presented digitally as submitted. For SDC 
documents, any labels or legends should be included in the original SDC file when submitted.  
For a list of all available file types and detailed instructions, please visit 
http://links.lww.com/A142.   
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SDC Call-outs  
Supplemental Digital Content must be cited consecutively in the text of the submitted 
manuscript. Citations should include the type of material submitted (Audio, Figure, Table, 
etc.), be clearly labeled as "Supplemental Digital Content," include the sequential list number, 
and provide a description of the supplemental content. All descriptive text should be included 
in the call-out as it will not appear elsewhere in the article.   
Example:   
We performed many tests on the degrees of flexibility in the elbow (see Video, Supplemental 
Digital Content 1, which demonstrates elbow flexibility) and found our results inconclusive.   
List of Supplemental Digital Content  
A listing of Supplemental Digital Content must be submitted at the end of the manuscript file. 
Include the SDC number and file type of the Supplemental Digital Content. This text will be 
removed by our production staff and not be published.  
Example:  
Supplemental Digital Content 1. wmv   
SDC File Requirements  
All acceptable file types are permissible up to 10 MBs. For audio or video files greater than 10 
MBs, authors should first query the journal office for approval. For a list of all available file 
types and detailed instructions, please visit http://links.lww.com/A142.   
Tables: Create tables using the table creating and editing feature of your word processing 
software (e.g., Word, WordPerfect). Do not use Excel or comparable spreadsheet programs. 
Provide a separate document for each table. Cite tables consecutively in the text, and number 
them in that order. Key each on a separate sheet, and include the table title, appropriate 
column heads, and explanatory legends (including definitions of any abbreviation not already 
defined in the text). Do not embed tables within the body of the manuscript. They should be 
self-explanatory and should supplement, rather than duplicate, the material in the text. In 
each table, the genus of each genus-species must be written out at its first appearance.   
Style: Stedman's Medical Dictionary (27th edition) and Merriam Webster's Collegiate Dictionary 
(10th edition) should be used as standard references. Refer to drugs and therapeutic agents by 
their accepted generic or chemical names, and do not abbreviate them. Use code numbers only 
when a generic name is not yet available. Capitalize the trade names of drugs and place them 
in parentheses after the generic names. To comply with trademark law, include the name and 
location (city and state/country) of the manufacturer of any drug, supply, or equipment 
mentioned in the manuscript. Use the metric system to express units of measure and degrees 
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Celsius or degrees Fahrenheit consistently throughout the manuscript to express temperatures, 
and use SI units rather than conventional units. Abbreviate "liter" in such forms as "3 units/L" 
and "5 mL"; write out when used alone (10 liters; 0.5-liter gavage). See also Day RA, ed. How to 
Write and Publish a Scientific Paper. 5th ed. Phoenix, AZ: The Oryx Press, 1998.   
Brief Reports: Papers for this section should be no longer than 5–6 double-spaced typed 
manuscript pages (fewer than 1500 words), 10 references and 1 figure or table. Word count 
does not include Title Page or Unstructured Abstract.   
Letters to the Editors: Letters to the Editors should pertain to articles published within the 
Pediatric Infectious Disease Journal or highlight important new clinical or laboratory insights.  
Text should contain 500 words or fewer and less than 5 references.   
Financial disclosure: In the cover letter, indicate all affiliations with or financial involvement 
in any organization or entity with a direct financial interest in the subject matter or materials 
of the research discussed in the manuscript (e.g. employment, consultancies, stock 
ownership). All such information will be held in confidence during the review process. Should 
the manuscript be accepted, the Chief Editors will discuss with the author the extent of 
disclosure appropriate for publication.   
  
After Acceptance  Open access   
LWW’s hybrid open access option is offered to authors whose articles have been accepted for 
publication. With this choice, articles are made freely available online immediately upon 
publication. Authors may take advantage of the open access option at the point of 
acceptance to ensure that this choice has no influence on the peer review and acceptance 
process. These articles are subject to the journal’s standard peer-review process and will be 
accepted or rejected based on their own merit.   
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual 
unrestricted online access to their published article to readers globally, immediately upon 
publication. The article processing charge for The Pediatric Infectious Disease Journal is 
$3,000. The article processing charge for authors funded by the Research Councils UK (RCUK) 
is $3,800. The publication fee is charged on acceptance of the article and should be paid 
within 30 days by credit card by the author, funding agency or institution. Payment must be 
received in full for the article to be published open access.   
  
Authors retain copyright: Authors retain their copyright for all articles they opt to publish 
open access. Authors grant LWW a license to publish the article and identify itself as the 
original publisher.   
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Creative Commons license: Articles opting for open access will be freely available to read, 
download and share from the time of publication. Articles are published under the terms of 
the Creative Commons License Attribution-NonCommerical No Derivative 3.0 which allows 
readers to disseminate and reuse the article, as well as share and reuse of the scientific 
material. It does not permit commercial exploitation or the creation of derivative works 
without specific permission. To view a copy of this license visit:  
http://creativecommons.org/licenses/by-nc-nd/3.0.   
  
Compliance with NIH, RCUK and other research funding agency accessibility requirements: A 
number of research funding agencies now require or request authors to submit the postprint 
(the article after peer review and acceptance but not the final published article) to a 
repository that is accessible online by all without charge. As a service to our authors, LWW 
identifies to the National Library of Medicine (NLM) articles that require deposit and 
transmits the post-print of an article based on research funded in whole or in part by the  
National Institutes of Health, Howard Hughes Medical Institute, or other funding agencies to 
PubMed Central. The revised Copyright Transfer Agreement provides the mechanism. LWW 
ensures that authors can fully comply with the public access requirements of major funding 
bodies worldwide. Additionally, all authors who choose the open access option will have their 
final published article deposited into PubMed Central.   
RCUK funded authors can choose to publish their paper as open access with the payment of 
an article process charge, or opt for their accepted manuscript to be deposited (green route) 
into PMC with an embargo.   
With both the gold and green open access options, the author will continue to sign the 
Copyright Transfer Agreement (CTA) as it provides the mechanism for LWW to ensure that 
the author is fully compliant with the requirements. After signature of the CTA, the author 
will then sign a License to Publish where they will then own the copyright.   
It is the responsibility of the author to inform the Editorial Office and/or LWW that they have 
RCUK funding. LWW will not be held responsible for retroactive deposits to PMC if the author 
has not completed the proper forms.   
  
FAQ for open access: http://links.lww.com/LWW-ES/A48   
  
Page proofs and corrections: Corresponding authors receive page proofs to check the 
copyedited and typeset article before publication. Portable document format (PDF) files of 
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the typeset pages and support documents (e.g., reprint order form) are sent to the 
corresponding author by E-mail. Complete instructions are provided with the E-mail for 
downloading and printing the files and for faxing the corrected page proofs to the publisher. 
Those authors without an E-mail address receive traditional page proofs. It is the author's 
responsibility to ensure that there are no errors in the proofs. Changes that have been made 
to conform to journal style stand if they do not alter the authors' meaning. Only the most 
critical changes to the accuracy of the content are made. Changes that are stylistic or are a 
reworking of previously accepted material are disallowed. The publisher reserves the right to 
deny any changes that do not affect the accuracy of the content. Authors may be charged for 
alterations to the proofs beyond those required to correct errors or to answer queries. Proofs 
must be checked carefully and returned within 24 to 48 hours of receipt, as requested in the 
cover letter accompanying the page proofs.   
  
Reprints: Authors receive a reprint order form with the page proofs that includes reprint 
costs. Reprint order forms should be returned to Author Reprint Department, Lippincott 
Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436. Reprints are 
normally shipped 6 to 8 weeks after publication of the issue in which the item appears.  
Contact the Author Reprint Department, Lippincott Williams & Wilkins, 351 W. Camden 
Street, Baltimore, MD 21201; Fax: 410-528-4434; E-mail: reprintsgroup@lww.com with any 
questions.   
  
Permissions: For permission and/or rights to use content for which the copyright holder is 
LWW or the society, please go to the journal's website and after clicking on the relevant 
article, click on the "Request Permissions" link under the "Article Tools" box that appears on 
the right side of the page. Alternatively, send an e-mail to customercare@copyright.com.   
For Translation Rights & Licensing queries, contact Silvia Serra, Translations Rights, Licensing  
& Permissions Manager, Wolters Kluwer Health (Medical Research) Ltd, 250 Waterloo Road,  
London SE1 8RD, UK. Phone: +44 (0) 207 981 0600. E-mail: silvia.serra@wolterskluwer.com  For 
Special Projects and Reprints (U.S./Canada), contact Alan Moore, Director of Sales,  
Lippincott Williams & Wilkins, Two Commerce Square, 2001 Market Street, Philadelphia, PA  
19103. Phone: 215-521-8638. E-mail: alan.moore@wolterskluwer.com   
For Special Projects and Reprints (non-U.S./Canada), contact Silvia Serra, Translations Rights,  
Licensing & Permissions Manager, Wolters Kluwer Health (Medical Research) Ltd, 250 Waterloo 
Road, London SE1 8RD, UK. Phone: +44 (0) 207 981 0600. E-mail:  
silvia.serra@wolterskluwer.com   
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Publisher's contact: Send corrected page proofs, color letters, and any other related materials 
to Emily Weisenreder, Emily.Weisenreder@wolterskluwer.com, 410-528-4102 (phone), 443-
451-8147 (fax), or mail to Emily Weisenreder, Wolters Kluwer Health, 351 W.  
Camden Street, Baltimore, MD 21201.   
  
Manuscript Checklist (before submission)   
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Title page (including conflicts of interest statement)   
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References double-spaced in US National Library of Medicine style   
Corresponding author and E-mail address designated (in cover letter and on title page)   
Permission to reproduce copyrighted materials or signed patient consent forms   
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Figures created/saved as TIFF, EPS, or PowerPoint files   
At least 3 suggested reviewers   
  
  




Appendix 3:  UCT Human Research Ethics Committee Approval for this study  
  
  
RCHKIR001  Dissertation for MPH   PART D:  APPENDICES   




    
  
  
RCHKIR001  Dissertation for MPH   PART D:  APPENDICES   
Part D: Page 52 of 50   










RCHKIR001  Dissertation for MPH   PART D:  APPENDICES   
Part D: Page 53 of 50   
Appendix 5:  Supplementary material (Manuscript Table 4.)  
  
  
  
 
  
